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ABSTRACT 
 
 Cancer cells exhibit an abnormal metabolic phenotype characterized by glycolysis 
and lactate fermentation in the presence of oxygen, a phenomenon known as the Warburg 
effect.  This dysregulated metabolism plays an important role in every aspect of cancer 
progression, from tumorigenesis to invasion and metastasis.  The Warburg effect is a 
common phenotype shared by most, if not all, cancer types.  It is especially prominent in 
metastatic tumors, which are notoriously resistant to treatment and responsible for the 
majority of cancer-related deaths.  Thus, metabolic therapies which target the Warburg effect 
could offer novel therapeutic options for most cancer patients, including those with 
aggressive or late-stage cancers.  The ketogenic diet is a high fat, low carbohydrate diet that 
induces a physiological state of nutritional ketosis – decreased blood glucose and elevated 
blood ketones.  It has been investigated as a cancer therapy for its potential to exploit the 
Warburg effect by restricting glucose availability to glycolysis-dependent tumors, and has 
been reported to slow cancer progression in some animal models as well as in anecdotal 
reports and small clinical studies in humans.  Interestingly, there is some evidence that the 
elevation in blood ketones induced by the ketogenic diet contributes to its anti-cancer effects, 
suggesting that ketone supplementation could possibly inhibit cancer progression on its own.  
Rapid growth outstrips a tumor’s ability to adequately perfuse its tissue, creating regions of 
tumor hypoxia which exacerbate the Warburg effect and promote a malignant phenotype.  
xi 
 
Hyperbaric oxygen therapy is the administration of 100% oxygen at elevated barometric 
pressure.  It supersaturates the blood with oxygen, increasing its diffusion distance into the 
tissues, and can therefore be used to increase intratumoral pO2 and reverse tumor hypoxia.  
Here we present evidence that the ketogenic diet, ketone supplementation, and hyperbaric 
oxygen therapy work individually and in combination to slow progression and extend 
survival in the VM-M3 model of metastatic cancer.  This study strongly suggests that these 
cost effective, non-toxic metabolic therapies should be further evaluated in animal and 
human studies to determine their potential clinical use.      
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CHAPTER 1: CANCER METABOLISM 
 
1.1 Chapter Synopsis  
Here I provide a brief review of cellular energy metabolism, including the mechanisms of 
ATP production through the anaerobic and aerobic pathways, with a special emphasis on glucose 
and ketone body metabolism.  The prevalence of these pathways are altered substantially in 
cancer cells, which exhibit a very unique metabolic phenotype characterized by lactate 
fermentation in the presence of oxygen.  This phenomenon is known as the Warburg effect and 
the dysregulated metabolic pathways which confer this phenotype play critical roles in every 
aspect of cancer progression, from tumorigenesis to metastasis.  A good understanding of the 
multifaceted and often underappreciated features of cancer metabolism will be critical for 
interpreting the rationale behind our proposed therapies and the data presented in the subsequent 
chapters of this dissertation.  Thus, the majority of this chapter will be devoted to an in-depth 
description of multiple causes and consequences of cancer metabolism, including mitochondrial 
dysfunction, altered reactive oxygen species (ROS) production and redox status, tumor hypoxia, 
generation of biosynthetic precursors, lactate production and the acidification of the tumor 
microenvironment, and oncogene and tumor suppressor gene interplay.  This chapter will also 
address the importance of cancer metabolism in the acquisition of a malignant phenotype, the 
most life-threatening and difficult to treat aspect of human cancer.  Since the Warburg effect is a 
shared feature of most, if not all cancers, and is especially prominent in metastatic tumors, 
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therapies which target this phenotype could be an effective treatment for many cancer patients, 
including those with aggressive or late-stage cancers.     
 
1.2 Cellular Energy Metabolism  
Energy metabolism includes the complex set of biochemical pathways which convert the 
food we eat into a usable form of energy for the cell, namely adenosine triphosphate (ATP).  The 
energy released from the hydrolysis of the terminal phosphate bonds of ATP (7.3 kCal) is used to 
power nearly all of the chemical reactions in the body.  It also provides a source of phosphate for 
protein phosphorylation, one of the most widely used methods of posttranslational modification 
and regulation of protein function.  ATP can be made by oxidizing several types of metabolic 
fuels, with carbohydrates and fats being some of the most important.  The intermediate 
metabolites formed by the partial oxidation of the major macronutrients enter the metabolic 
pathways at various stages and their fates are dependent upon the cellular and systemic energy 
status, metabolic requirements of the particular cell and tissue type, and presence of oxygen, 
among other factors. 
Biosynthesis of ATP occurs with the phosphorylation of adenosine diphosphate (ADP) 
by one of two methods: substrate level phosphorylation (SLP), which does not require oxygen, 
and oxidative phosphorylation (OXPHOS), which does.  SLP occurs in two steps of glycolysis, 
and is also used to produce guanosine triphosphate (GTP) in the Kreb’s cycle, which can be 
converted to ATP.  OXPHOS involves the oxidation of the NADH and FADH2 hydrogen carriers 
by the components of the electron transport chain (ETC) on the inner mitochondrial membrane.  
Electrons are passed between the complexes of the ETC in a series of oxidation-reduction 
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reactions.  The final electron acceptor of the ETC is molecular oxygen, and its reduction 
produces H2O.  During electron transfer, H
+ protons are pumped into the inner membrane space.  
Sequestering H+ across the inner membrane creates an electrochemical gradient called the proton 
motive force which provides the potential energy used to power ATP synthesis.     
 
1.2.1 Carbohydrate and Glucose Metabolism 
In a fed state, when eating a standard Western diet, glucose is the primary metabolic fuel 
for the cell.  Dietary carbohydrates are digested to glucose, a six carbon monosaccharide which 
is transported into the cell by a family of membrane proteins called the glucose transporters 
(GLUT).  Glucose is converted to two pyruvate molecules through a series of nine enzymatic 
reactions collectively called glycolysis.  Two reactions of glycolysis, those catalyzed by 
phosphoglycerate kinase and pyruvate kinase, produce ATP by SLP.  The fate of pyruvate 
oxidation primarily depends on the cellular oxygen status.  When oxygen availability is limited, 
such as in the exercising muscle, pyruvate is converted to lactate by lactate dehydrogenase.   This 
pathway is called anaerobic respiration, or fermentation.  It produces another ATP by SLP and 
replenishes the hydrogen carrier NAD+ which is reduced during glycolysis.  Under normal 
oxygen conditions, the cell will preferentially utilize aerobic respiration in the mitochondria to 
oxidize pyruvate.  Pyruvate is converted to acetyl CoA via the pyruvate dehydrogenase complex 
and shuttled into the mitochondria to participate in the Kreb’s cycle.  The Kreb’s cycle mediates 
the complete oxidation of the remaining carbons from glucose, producing CO2 and reducing 
NAD+ to NADH+H+ and FAD to FADH2.  These hydrogen carriers participate in mitochondrial 
energy metabolism in the aforementioned steps.  Aerobic respiration is a much more efficient 
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mechanism of energy production than fermentation, producing nearly ten times as much ATP per 
glucose molecule.  Thus, OXPHOS is responsible for approximately 90% of the ATP produced 
in mammalian cells.  When blood glucose levels are low, such as during carbohydrate or calorie 
restriction, glucose is released from glycogen stores in the muscle and liver.  When energy 
symbols like ATP, NADH, and citrate are high, glucose metabolites are shunted towards fatty 
acid synthesis to contribute to stored fat reserves.   
 
1.2.2 Fat Metabolism and the Ketone Bodies 
 Fatty acids from dietary or stored fats undergo β-oxidation to produce acetyl CoA which 
can combine with oxaloacetate to enter the Kreb’s cycle as citrate.  The metabolic fate of acetyl 
CoA from fatty acids is the same as the previously described steps in glucose metabolism.  When 
glucose and insulin levels are low, such as during carbohydrate or calorie restriction or 
starvation, oxaloacetate in the liver is shipped into the cytosol to participate in gluconeogenesis.  
Thus, acetyl CoA from fatty acid oxidation does not enter the Kreb’s cycle and is shunted 
towards ketogenesis instead.  A series of three enzymatic reactions converts acetyl CoA to 
acetoacetate (AcAc), one of the three major ketone bodies, or ketones.  AcAc can be reduced to 
produce β-hydroxybutyrate (βHB) or decarboxylated to produce acetone, the two other ketone 
bodies.  Ketones are produced by the liver and released into circulation where they are taken up 
by extra-hepatic tissues and metabolized for energy.  Ketones are transported directly into the 
mitochondria where they are converted back into acetyl CoA which enters the Kreb’s cycle, 
bypassing glycolysis altogether.  From here, the fate of acetyl CoA is the same as in glucose 
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metabolism: the Kreb’s cycle produces NADH+H+ and FADH2 which provide electrons for use 
in the ETC, establish the proton motive gradient, and power ATP synthesis through OXPHOS.   
 
1.3 Cancer Metabolism and the Warburg Effect 
In 2000, Hanahan and Weinberg published a landmark review describing the fundamental 
features of neoplasms which they termed the hallmarks of cancer.  The hallmarks included 
sustaining proliferative signaling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis, and resisting cell death [1].  
In an updated version released in 2011, they added deregulating cellular energetics as an 
emerging hallmark [2].  Although described as emerging, the altered metabolic phenotype of 
cancers has been known for nearly a century, long before most of the other hallmarks were 
discovered or understood.  In the 1950s, the German biochemist Otto Warburg reported that, 
unlike healthy cells, cancer cells undergo high rates of glucose uptake and lactate fermentation in 
the presence of oxygen [3].  This phenomenon is known as the Warburg effect, and is often also 
described as aerobic glycolysis.  In the decades since, the Warburg effect has been observed in 
most, if not all, cancer types [4-6].  Cancer cells exhibit glycolytic rates of up to 200 times 
greater than that of their normal cellular counterparts [7].  Many cancers also exhibit enhanced 
glutamine oxidation through the Kreb’s cycle; however, it is unclear if this phenotype is as 
ubiquitous as the Warburg effect.  The Warburg effect serves as the basis for one of the most 
important clinical diagnostic tools, the fluorodeoxyglucose positron emission tomography (FDG-
PET) scan [8].  Because of their high glycolytic demand, tumors take up radioactively labeled 
glucose (18F-FDG) at a much higher rate than surrounding normal tissue, allowing visualization 
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by positron emission tomography.  Attesting to the near universal presence of the Warburg 
effect, FDG-PET imaging has a 90% or greater specificity and sensitivity for most cancers [9, 
10].  18F-FDG avidity is exceptionally high in metastatic cancers, making FDG-PET imaging 
very useful for identifying metastatic lesions [11], and supporting the observation that the 
Warburg effect correlates strongly with the aggressive and invasive potential of the tumor as well 
as cancer progression [12, 13].   
 
1.3.1 Metastasis 
 Metastasis is the spreading of a cancer from the site of origin to another part of the body.  
Metastasis is the major cause of morbidity and mortality in cancer patients, responsible for over 
90% of cancer-related deaths [14].  Thus, metastasis is a phenotype of cancer that deserves 
special attention and should be considered within the context of any potential therapeutic 
strategies.  Most cancers metastasize through the blood or lymphatic vasculature, although some 
tumors shed malignant cells directly into body cavities, a process called transcoelomic 
metastasis.  The specific mechanisms of intravascular metastasis are not fully understood; 
however, the general steps include degradation and invasion of the basement membrane, 
intravasation into the vasculature, dissemination and survival in the circulation, extravasation at a 
distal tissue, and the formation of metastatic lesions there.   
Epithelial-to-mesenchymal transition (EMT) is a known embryologic program involving 
a series of phenotypic and molecular alterations in which epithelial cells acquire mesenchymal 
characteristics.  It has been suggested that during tumor development, cancer cells re-activate 
this latent program to transition to more aggressive phenotype.  It is currently the most 
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commonly hypothesized mechanism by which primary tumor cells initiate invasion and 
metastasis [15].  However, some have suggested that EMT in cancer may be a consequence of 
the in vitro environment, and the degree to which it occurs in vivo remains largely unknown [16].  
Loss of epithelial markers such as E-cadherin, desmoplakin, and plakoglobin, accumulation of 
nuclear β-catenin, and an upregulation of mesenchymal markers including fibronectin and 
vimentin are often seen in malignant cancer cells in vitro [17-21].  Transcription factors which 
mediate the changes in epithelial and mesenchymal marker expression include SNAIL, SLUG, 
TWIST, and ZEB [22-26].  EMT is thought to occur at the invasive front of the tumor under 
influence from signals released by stromal cells in the tumor microenvironment [27].  Indeed, 
SNAIL has been shown to be up-regulated preferentially at the tumor-stromal border in larynx 
and colon carcinomas, and its expression was inversely related to E-cadherin expression [28].  
By adopting a mesenchymal phenotype, cancer cells acquire the ability to degrade and invade the 
basement membrane, and to intravasate into the blood and lymph circulation.  It is hypothesized 
that once the cells arrive in distal tissues, they revert to an epithelial phenotype through a reverse 
EMT process termed mesenchymal-to-epithelial (MET) transition in order to establish metastatic 
tumors [29, 30].   
 Cancers appear to follow a general pattern of metastatic colonization, with certain cancer 
types preferentially metastasizing to specific target organs.  Homing refers to the migration of a 
cell to a specific tissue or organ and can be used to describe the behavior of metastatic cells.  
Proposed explanations for metastatic cell homing include the targeted metastasis of tumor cells 
which express the adhesion molecules for endothelial cells preferentially expressed on the 
endothelium of specific organs [31].  Similarly, others have suggested that tumors exhibit a 
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preference of metastasizing to tissues rich in growth factors or chemokines for which the cancer 
cells possesses receptors [31].   
A less widely known hypothesis regarding the origin of metastatic cancer involves the 
transformation of or fusion with immune cells, most notably macrophages, in the tumor 
microenvironment [32-35].  Macrophages naturally perform the activities of metastatic cells by 
surviving in circulation, and moving into and out of tissues and the vasculature.  Interestingly, 
many human cancers also exhibit many molecular and behavioral characteristics that are 
otherwise considered specific to macrophages or other immune cells, including expression of 
certain antigens as well as phagocytic and fusogenic capabilities [32, 33].  Macrophages are 
naturally fusogenic and will fuse with other macrophages to produce giant multinucleate cells 
during the immune response.  Interestingly, tumor cell-macrophage fusion has been observed 
both in vitro and in many animal and human tumors in vivo [32, 36-38].  This observation has led 
to the hypothesis that these fusion events could produce cells which retain the proliferative, 
neoplastic phenotype of the tumor cell while acquiring the behavioral characteristics of 
macrophages, thus allowing them to travel through the body, evade the immune system, and 
colonize distal tissues [35, 36, 38-40].  Indeed, induced fusion of melanoma cells with 
macrophages in vitro created hybrid cells with enhanced metastatic potential when grown in vivo 
[40].  Furthermore, as macrophages are mesenchymally-derived, this acquisition could contribute 
in part to the EMT-like changes observed in many metastatic cells.  Compared to the degree of 
inquiry put forth towards the role of EMT in metastasis, only a very few studies have examined 
the specific role of macrophages in the origin of cancer metastasis; however, the existing data 
strongly indicates a need for further investigation into this novel idea.   
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Recently, the discovery of cancer stem cells (CSC), a subpopulation of tumor cells with 
self-renewal and pluripotent capabilities has led to the hypothesis that metastatic lesions may 
arise specifically from a pool of CSC within the primary tumor [41].  There is now substantial 
evidence to support the existence of CSC in human cancers and to suggest that these cells are 
specifically responsible for tumorigenesis, initiation of metastasis, clinical resistance to 
therapies, and recurrence of tumors following periods of remission.  There has been little success 
in identifying genetic markers which are consistently expressed by CSC; however, the glycolytic 
phenotype of the Warburg effect is a fundamental feature of these cells [42].  This is not 
surprising since a glycolytic phenotype is present in normal stem cells of healthy tissues.  The 
recent development of human induced pluripotent stem cells (iPSCs), which earned Gurdon and 
Yamanaka the 2012 Nobel Prize in Medicine, has provided an incredible tool for understanding 
pluripotency and cellular differentiation, or dedifferentiation, with far-reaching implications for 
investigation into the CSC population.  Indeed, iPSCs share many features with CSC.  The four 
transcription factors used to induce pluripotency in Gurdon and Yamanaka’s method – Oct4, 
Sox2, Klf4, and c-Myc – were all previously known for their oncogenic activities [42].  
Importantly, studies on iPSCs have demonstrated that the reprogramming of somatic cells to 
pluripotent stem cells requires acquisition of a glycolytic phenotype, while inhibiting glycolysis 
enzymes prevents this reprogramming event [42-49].  It is possible that the reprogramming 
events in both iPSCs and CSCs are affected by the Crabtree effect (inhibition of respiration by 
elevated glucose concentrations) which is often a confounding factor in the culture environment 
[50]; however, it does not appear that this possibility has been adequately examined to date [51, 
52].   
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Taken altogether, these data strongly suggest that the Warburg effect is a critical 
component of tumorigenesis and metastasis and targeting the glycolytic phenotype of cancer 
cells could provide significant therapeutic potential.  Indeed, many aspects of EMT, invasion, 
and metastasis are influenced by or mediated by cancer metabolism.  A discussion of these 
mechanisms will be included in the following sections.   
 
1.3.2 Causes and Consequences of Cancer Metabolism  
 As described, fermentation is an inefficient mechanism of energy production 
compared to OXPHOS.  Thus, it is not immediately clear why rapidly proliferating tumors with 
high metabolic demands would utilize this method.  This paradox has prompted researchers to 
investigate and hypothesize multiple causes and consequences of the Warburg effect which may 
underlie this unique cancer metabolism.  The Warburg effect is a consistent and well-established 
metabolic phenotype of cancer cells; however, alterations in cancer energy metabolism are 
complex and require insight far beyond the balance between fermentation and OXPHOS.  Some 
important aspects which should be discussed include mitochondrial dysfunction, altered ROS 
production and redox status, tumor hypoxia, generation of biosynthetic precursors, lactate 
production and the acidification of the tumor microenvironment, and oncogene and tumor 
suppressor gene interplay.   
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1.3.2.1 Mitochondrial Dysfunction  
The role of the mitochondria in carcinogenesis and tumor progression is multifaceted and 
remains incompletely understood.  The degree to which mitochondria are functional, or 
dysfunctional, in cancers is a hotly debated topic [52-54].  Unlike in cancer, the majority of ATP 
energy produced by healthy cells is derived from OXPHOS in the mitochondria.  Warburg 
originally hypothesized that impaired mitochondrial OXPHOS forces cancer cells to acquire 
their fermentative phenotype (Warburg effect) in order to preserve energy production and 
maintain viability [3].  He further proposed that this metabolic damage was the instigating cause 
of tumorigenesis, a proposition known as the Warburg hypothesis [55].  In the decades since 
Warburg’s work and hypotheses, mitochondrial abnormalities have been reported in most if not 
all tumors examined [53], although its specific role in cancer development remains unclear.        
A review of 20 studies consistently demonstrated decreased mitochondrial numbers in 
tumor samples compared to healthy tissue of the same origin [56].  Other studies reported that 
decreased mitochondrial DNA (mtDNA) copy number is associated with higher histological 
grade, propensity for metastasis, and worse clinical prognosis and overall survival in patients 
with breast cancer and osteosarcoma [57, 58].  Mitochondria have an important morphological 
structure which facilitates their function.  Electron transport occurs along the folds of the inner 
mitochondrial membrane called cristae, maximizing surface area for optimal ATP production.  
Abnormalities in mitochondrial morphology are indicative of mitochondrial dysfunction and 
correlated with respiratory insufficiency [59].  The morphology of tumor mitochondria vary 
significantly from that of healthy cells.  Many studies have shown that tumor mitochondria often 
exhibit partial or total cristolysis.  Ultrastructural analysis of human brain tumors by electron 
microscopy found abnormal mitochondrial morphology in all samples studied [60].  
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Mitochondrial swelling and partial or total cristolysis of the inner membrane was the most 
consistent phenotype observed.  In a similar study of almost 800 breast tumor biopsies, 
approximately 60% of tumor samples examined lacked any identifiable mitochondria [61].  Of 
the 40% of tumors in which mitochondria were present, half contained only very few 
mitochondria which were morphologically abnormal – swollen, vacuolated, and exhibiting 
cristolysis.  Interestingly, the degree of mitochondrial dysfunction correlated with a more 
anaplastic and aggressive histological phenotype.   
The lipid composition of the inner mitochondrial membrane also differs widely between 
cancer cells and their normal counterparts, with abnormalities in cholesterol and specific 
phospholipid content [62, 63].  Cardiolipin (CL) is a mitochondrial specific phospholipid that 
regulates electron transport, OXPHOS, and is essential for mitochondrial coupled respiration 
[64-71].  Seyfried and colleagues demonstrated that CL content is significantly lower in brain 
tumor mitochondria compared to normal brain tissue in mice [72].  Similar results were found in 
rhabdomyosarcoma cells, and in both studies, CL abnormalities were linked to decreased 
complex I activity [72, 73].  Reduced expression of or mutations in the genes encoding the ETC 
complexes have been reported in several different cancers as well [50, 53, 74-77].  Furthermore, 
decreased expression of the β-subunit of ATP synthase, the mitochondrial enzyme which couples 
electron transport to ATP synthesis via OXPHOS, has been reported in liver, kidney, colon, 
breast, gastric, oesophageal, and lung carcinomas [78, 79].   
Mitochondrial uncoupling refers to the dissipation of the proton motive gradient across 
the inner mitochondrial membrane and is characterized by an uncoupling of electron transport 
from ATP synthesis by OXPHOS.  Uncoupling can be induced by uncoupling proteins (UCPs) 
or can be a consequence of inner membrane dysfunction caused by abnormal lipid composition, 
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most notably CL.  Several studies have demonstrated that mitochondrial uncoupling occurs in 
tumors of varied tissue types.  UCP expression is up-regulated in some tumors [80, 81].  One 
study showed that H+ back-decay – the leaking of H+ protons into the mitochondrial matrix from 
the inner membrane space – was eightfold greater in Ehrlich ascites tumor mitochondria 
compared to normal mitochondria [82].   Brown adipose tissue contains naturally uncoupled 
mitochondria which use electron transport to generate heat for thermoregulation rather than 
produce ATP by OXPHOS.  Therefore, heat production is considered a hallmark of 
mitochondrial uncoupling.  Many human tumors generate heat, leading to the investigation of 
thermography, or heat mapping, as a potential diagnostic tool [83].  In a study in human patients 
with melanoma, thermography differentiated malignant melanoma lesions from benign lesions 
with significant sensitivity and selectivity [84].  Numerous other mitochondrial abnormalities are 
reported in cancers across tissue type, including mtDNA mutations [85, 86], abnormal fission-
fusion [60], and altered mitochondrial membrane potential [87-89].  Further support of 
mitochondrial dysfunction in cancer is illuminated by studies in which transfer of healthy 
mitochondria into cancer cells suppress the neoplastic phenotype [90-93], leading some to 
suggest that healthy mitochondria function as a tumor suppressor [52].  It is important to note 
that aside from the metabolic responsibilities of the mitochondria, they are also critically 
involved in calcium homeostasis, control of cell death, and redox status – three phenomenon 
which are also drastically altered in cancers [94].   
 Taken together, these data strongly suggest that decreased capability and/or contribution 
of mitochondrial respiration and function is a fundamental feature of cancer.  Despite such an 
overwhelming body of evidence, many researchers adhere to the notion that mitochondrial 
respiration is not impaired and the Warburg effect is simply an adaptive phenotype [10].  This 
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hypothesis is based largely on studies which demonstrate that cancer cells continue to consume 
oxygen and produce CO2.  It is important to note that although respiring mitochondria will 
consume O2 and produce CO2, it is not necessarily true that oxygen consumption is coupled to 
ATP production.  This is especially true for uncoupled mitochondria.  Indeed, studies have 
shown that oxygen consumption is greater in cells with greater tumorigenic potential, but these 
cells rely less heavily on mitochondrial respiration compared to those with less tumorigenic 
potential [95].  There is no sophisticated method to determine exactly what proportion of cellular 
ATP is derived from SLP in glycolysis and the Kreb’s cycle compared to functional OXPHOS in 
the mitochondria.  However, it is unclear and unlikely that tumors displaying the wide variety of 
mitochondrial abnormalities previously described could maintain normal respiration.  As such, 
many scientists agree with Warburg’s original hypothesis: that the Warburg effect and associated 
metabolic phenotype of cancer is primarily caused by mitochondrial dysfunction and respiratory 
insufficiency [52, 96].      
 
1.3.2.2 Altered ROS Production and Redox Status 
As electrons are transferred between the complexes of the mitochondrial electron 
transport chain (ETC), some are captured by molecular oxygen to form the superoxide anion (O2
-
∙).  O2-∙ is dismutated to hydrogen peroxide (H2O2) by the superoxide dismutase (SOD) enzymes.  
H2O2 is less damaging than O2
-∙ and is freely permeable through cellular membranes, making it a 
useful cellular signaling molecule.   In the presence of iron, H2O2 reacts to form the hydroxyl 
radical (∙OH) via the Fenton reaction.  O2-∙ can react with another free radical, nitric oxide (NO), 
to form peroxynitrite (ONOO-).  ∙OH and ONOO- are highly reactive.  They induce oxidative 
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damage onto DNA, proteins, and lipids and are responsible for much of the toxicity associated 
with ROS.  Although once thought of only as toxic byproducts of metabolism, it is now 
understood that ROS serve as important signaling molecules in healthy cells.   Low levels of 
ROS are produced during normal mitochondrial metabolism while damaging levels of potent 
oxidizers are kept in check by endogenous antioxidant systems like SOD, catalase, and 
glutathione peroxidase (GPx) [97, 98].   
It is thought that ROS production increases when electron transport is inhibited in the 
ETC [99, 100].  Mutations in the nuclear and/or mitochondrial genes encoding the ETC 
complexes increase ROS production in cancers [99].  It is well established that basal elevation of 
ROS is a consistent phenotype in cancers across tissue types [101], likely due to widespread 
mitochondrial damage [102].  Chronic inflammation from sustained hyperglycemia, infection, or 
exposure to chemicals like tobacco, is also a major source of ROS production in tumors [101].  
Elevated ROS confer a growth advantage to the tumor in many ways and play a significant role 
in tumorigenesis and progression [103].  Growth factor signaling often works through receptor 
tyrosine kinase (RTK) cascades to drive cell proliferation.  Several of these RTKs act through 
ROS-dependent mechanisms.  Epidermal growth factor receptor (EGFR) and platelet-derived 
growth factor (PDGF) signaling work in part through H2O2 signaling mechanisms [104, 105].   
H2O2 oxidizes PTEN to prevent inactivation of RTK signaling through Akt.  ROS-induced 
stabilization of HIF-1 enhances the transcriptional activation of numerous glycolytic, 
proliferative, and pro-survival genes [106].  Furthermore, mtDNA is especially vulnerable to 
oxidative damage due to its close proximity to ETC-generated ROS [107].  Like nuclear 
mutations, mtDNA mutations are heavily implicated in malignant transformation and cancer 
progression [108-110]; however, not all tumors contain pathological mtDNA mutations [111].  
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The nuclear genome is also a major target of ROS, creating widespread mutations and DNA 
strand breaks.  This enhanced mutability further contributes to the collection of oncogenes and 
tumor suppressor gene mutations in tumor cells which undergo clonal expansion to produce a 
more malignant phenotype [112].  The cancer-promoting effects of ROS have prompted efforts 
to develop therapies which inhibit ROS production by tumors [113].   
This chronic elevation in ROS production is kept at sub-lethal levels by an up-regulation 
of endogenous antioxidant systems [97, 98], allowing cancers to survive and thrive in a redox 
state which would be toxic to healthy cells.  There still exists, however, a threshold point above 
which ROS will irreversibly damage and induce apoptosis in cancer cells [114].  While the 
cancer-promoting effects of ROS have incited the proposal and testing of anti-oxidant therapies 
for cancer, recognition of cancer susceptibility to further oxidative stress have spurred 
development of pro-oxidant therapies with the intention of pushing cells past their oxidative 
breaking point to incite cell death [113].  The antioxidant ascorbic acid (vitamin C) is being 
investigated in clinical trials as a potential cancer therapy [115], but it may actually work as a 
pro-oxidant at very high doses [116].  All current non-surgical standard therapies, including 
radiation and chemotherapy, work in part by enhancing ROS production [113].  This paradoxical 
phenomenon has led to the common understanding that ROS is truly a double-edged sword for 
cancer, which can be exploited by both the tumor, researcher, and patient in multiple ways to 
either promote or inhibit malignant progression [99].   
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1.3.2.3 Tumor Hypoxia 
Hypoxia in solid tumors is a well-documented phenomenon [117].  Normal tissue oxygen 
tension is highly tissue-specific, but typically ranges between 30-60 mmHg [118].  Intratumoral 
oxygen concentrations vary widely, ranging on average from 2.5 to 30 mmHg, with remarkable 
heterogeneity even within a single tumor [118].  In order to grow larger than approximately 
1mm3, tumors must stimulate angiogenesis to supply blood and nutrients to the growing tumor 
[119].  Under the influence of chaotic signaling cascades induced by oncogene activation, these 
new blood vessels are often malformed, immature, leaky, and unable to adequately perfuse the 
entire tumor [120].  Regions of the tumor which are not adequately vascularized become either 
transiently or chronically hypoxic [117].  Hypoxia is present even in small tumors, and 
preclinical studies have demonstrated that tumors that grow to 4 to 10 mm in diameter exhibit 
very large hypoxic regions [121, 122].  Oxygen tensions in the center of large tumors often 
approach 0 mmHg, creating areas of central necrosis [123].      
Tumor hypoxia dramatically affects malignant progression and therapeutic response.  It 
has been correlated to poor clinical prognosis in a variety of human cancers, including head and 
neck, uterine, cervical, and soft tissue sarcomas [124-126].  Radiation and many chemotherapies 
work by causing tumors to over-produce ROS which kill the cell by inflicting widespread lipid, 
protein, and DNA oxidative damage and inducing apoptosis and mitochondrial damage.  
Hypoxia stimulates ROS production largely for signaling purposes [127]. However, since 
oxygen is the substrate for ROS generation, hypoxia effectively prevents large quantities of ROS 
from being produced in response to therapeutic insult [128].  Indeed, the efficacy of radiation 
therapy is directly proportional to tissue pO2 [128].  The insufficient blood supply which induces 
hypoxia also prevents drug delivery to avascular regions within the tumor, further contributing to 
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chemotherapy resistance [129].  Rather than succumbing to treatment, hypoxic cells survive by 
entering a non-proliferative state [130].  After removal of therapeutic pressure, these hypoxic 
cells undergo clonal expansion to repopulate recurrent tumors which often have a highly 
malignant phenotype and are resistant to subsequent treatment [131-134].  Cancerous tumors 
adapt to nutrient and oxygen deprivation by three major mechanisms – activating angiogenesis, 
inhibiting apoptosis, and induction of the glycolytic shift – which eventually allow them to 
escape the confines of the primary tumor and metastasize to distal regions in the body [118].  
These adaptations are mediated in part through tumor hypoxia and expression of the hypoxia 
inducible factor-1 (HIF-1) transcription factor.  
Stability of HIF-1α, the regulatory subunit of HIF-1, is dependent on tissue pO2.  Under 
normal oxygen tensions, proline residues on HIF-1α are hydroxylated by prolyl hydroxylases 
(PHDs) which serve as a major oxygen sensing mechanism in the cell [135].  This hydroxylation 
event allows HIF-1α to be recognized, ubiquitinated, and targeted for proteasomal degradation 
by the von Hippel Lindau (vHL) E3 ubiquitin ligase and tumor suppressor.  During hypoxia, 
HIF-1α is not hydroxylated by PHDs nor ubiquitinated by VHL, but rather it accumulates and 
forms complexes with HIF-1β and other complex subunits to form the functional HIF-1 
transcription factor.  HIF-1 translocates to the nucleus where it directly regulates the expression 
of over 60 genes involved in energy metabolism and survival [136, 137].  However, the 
pleiotropic response to HIF-1 can alter the expression of nearly 500 genes [138].  HIF-1 binds to 
a conserved sequence in the promoter region of HIF-responsive genes called hypoxia responsive 
element (HRE).  In healthy tissues, HIF-1 signaling serves as a mechanism to promote survival 
during mild or transient hypoxia, such as in the exercising muscle.  Chronic or severe hypoxia-
induced HIF-1 signaling will initiate apoptosis through p53 [139], but this pathway is commonly 
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inactivated in malignant cells [140].  Rather, the dysregulated vascular environment of hypoxic 
tumors stimulates HIF-1 activity which confers potent growth and survival benefits without 
proper inhibitory feedback, promoting unbridled proliferation, invasion, and metastasis [136, 
141].  Experimentally, HIF-1α gain of function (GOF) manipulations increase tumor growth rate, 
angiogenesis, and metastasis while LOF elicits the opposite effects [106].  HIF-1 signaling in 
cancer is extensive, and its role has been expertly reviewed [106, 142].  Collectively, these 
studies show that HIF-responsive genes play vital roles in virtually every aspect of cancer 
biology, including immortalization [143], resistance to apoptosis [126], genomic mutability 
[144], immune evasion [145], tumor growth and proliferation [146], angiogenesis [147], energy 
metabolism [136], pH regulation [148], dedifferentiation [149], radio- and chemo-resistance 
[150], EMT [151], invasion [152], and metastasis [153].  
The Angiogenic Switch.  During hypoxia, angiogenic factors are secreted by tumor and 
stromal cells, including endothelial cells, fibroblasts, and infiltrating immune cells.  Vascular 
endothelial growth factor (VEGF) is one of the most potent angiogenic factors and is the most 
commonly expressed cytokine induced by hypoxia [154].  HIF-1 signaling enhances the 
expression of VEGF.  High blood levels of VEGF is correlated with poor prognosis in 
pancreatic, prostate, breast, renal, colorectal, and head and neck cancers [155-161].  The blood 
vessels formed by VEGF signaling in tumors are immature and facilitate chaotic blood flow, 
which in turn cause further hypoxia.  This creates a positive feedback system wherein hypoxia 
can be considered both a cause and consequence of tumor angiogenesis [118].  The expression of 
many other angiogenic factors is enhanced during the angiogenic switch, including platelet-
derived growth factor (PDGF), angiogenin, epidermal growth factor (EGF), fibroblast growth 
factor (FGF), and transforming growth factor-β (TGF-β) [118].  Many of these signaling 
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molecules also stimulate growth and proliferation.  In this way, the signaling initiated by the 
angiogenic switch promotes tumor growth while simultaneously stimulating the new blood 
vessel formation which is required for further tumor growth.  Subsequently, the immature blood 
vessels formed by this cycle exacerbate the hypoxic signaling which ensures further growth 
factor stimulation.  
Deregulation of Apoptosis.  Cancer cells will increase their metabolic rate to maintain 
anabolic processes and energy production during hypoxia [118, 162, 163].  Mitochondrial 
damage exacerbates hypoxia-induced ROS production, which contributes to DNA damage and 
the inactivation of important tumor suppressor pathways [102].  While normal cells possess 
functional cell cycle checkpoints and repair mechanisms to prevent cell cycle progression or 
induce apoptosis in the face of DNA damage, the enhanced mutability of cancer cells eventually 
selects for cells which have deactivated these protective mechanisms.  p53 and Rb are two of the 
most important regulators of DNA damage response mechanisms and both are commonly 
mutated or functionally absent in cancers [140, 164].  Chronic or severe hypoxia initiates cell 
death through HIF-1 stimulation of p53 in healthy tissues, but fails to do so in cancer cells with 
dysregulated p53.  Hypoxia also up-regulates anti-apoptotic Bcl-2 family members like Bcl-2 
and Bcl-Xl, while inhibiting translocation of the pro-apoptotic Bax to the mitochondrial 
membrane, further establishing resistance to apoptosis [130, 165, 166].  Thus, tumor hypoxia 
promotes the clonal expansion of highly malignant cells that are resistant to cell death. 
Glycolytic shift.  The faulty vasculature in growing tumors induces not only oxygen 
deprivation, but nutrient deprivation as well.  Normally, approximately 90% of cellular ATP is 
produced by mitochondrial aerobic respiration, an oxygen-dependent process.  During hypoxia, 
activation of HIF-1 enhances the transcription of glucose transporters (GLUT) and glycolytic 
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enzymes to maintain energy production via substrate level phosphorylation [136, 141, 167].  
Pyruvate from glycolysis is not oxidized in the mitochondria, but is shunted towards lactate 
fermentation to produce minimal ATP and replenish NAD+.  In order to satisfy cellular energy 
requirements, glycolysis and fermentation rates must increase significantly.  The Warburg effect 
describes how this phenomenon occurs in tumors regardless of tumor oxygenation.  When 
present, however, tumor hypoxia enhances glycolysis, fermentation, and the Warburg effect.  
Thus, hypoxia stimulates the glycolytic shift which preserves energy production to support 
cellular function and survival in response to nutrient deprivation.   
Invasion and Metastasis.  Individually, hypoxia and EMT have been considered crucial 
events in cancer progression and acquisition of a metastatic phenotype. Recent evidence 
suggests, however, that alterations in tissue pO2 and the hypoxic signaling mechanisms mediated 
by HIF may be crucial triggers and mediators of EMT.   Hypoxia significantly enhances the 
production of TGF-β in myeloid, mesenchymal, and cancer cells [168-171].  TGFβ works 
through both SMAD and non-SMAD pathways to promote tumor progression and invasion, and 
mediate EMT.  TGF-β-SMAD signaling induce the expression of SNAIL and ZEB.  SMAD3/4 
complex with SNAIL to inhibit the expression of E-cadherin [172].   SMADs also regulate the 
activation of β-catenin to induce EMT [173-175].  Non-SMAD TGF-β signaling cross-talks with 
other oncogenic pathways like Ras/MAPK, Wnt/β-catenin, and NFκB to promote acquisition of 
the mesenchymal phenotype [176-181].  The Notch pathway is important for stem-cell 
maintenance during development and regulation of differentiation in adult tissues.  Notch is also 
influenced by hypoxia [182, 183].  Notch signaling has been shown to mediate hypoxia-induced 
motility and invasion in cervical, ovarian, colon, and glioma cells [184].  HIF-1 activation also 
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mediates EMT by modulating the expression of the SNAIL, SLUG, TWIST, and ZEB 
transcription factors [151, 185].      
 
1.3.2.4 Generation of Biosynthetic Precursors 
The pentose phosphate pathway (PPP) is a divergent metabolic pathway from glycolysis 
which plays an important role in cellular proliferative rate and redox balance.  Rather than being 
isomerized to fructose-6-phosphate (F6P) in glycolysis, glucose-6-phosphate (G6P) is converted 
to ribose 5-phosphate (R5P) through a series of enzymatic reactions, generating NADPH in the 
process.  R5P and NADPH are important biosynthetic precursors for nucleotide and lipid 
synthesis, respectively.  Thus, PPP activity is significantly enhanced for increased cellular 
proliferation [186].  One consequence of the increased glycolytic rate associated with the 
Warburg effect is increased flux through the PPP.  In cancer cells, the PPP provides 
approximately 85% of the pentose phosphates incorporated into newly synthesized DNA [187].  
Glucose-6-phosphate dehydrogenase (G6PD), the enzyme responsible for shuttling G6P into the 
PPP, is up-regulated in many cancers and is now considered to be an oncogene [188].  p53 is an 
inhibitor of G6PD [189], but its common inactivation in tumors allows dysregulated and 
excessive PPP flux [190].   
The PPP also plays a significant role in maintaining endogenous antioxidant capacity, as 
NADPH is required for regeneration of reduced glutathione (GSH).  GSH prevents oxidative 
stress by neutralizing damaging free radicals.  As described, tumors thrive in a state of elevated 
basal ROS which promotes their growth and proliferation [99].  Enhanced GSH protects cancer 
cells against oxidative stress-induced apoptosis.  Since radiation and many chemotherapies work 
23 
 
by overproducing ROS in the tumor, elevated flux through the PPP is widely considered to 
mediate some degree of clinical treatment resistance [186].  Indeed, G6PD expression is further 
enhanced following ionizing radiation and confers protection against radiation-induced cell death 
[191].   
 
1.3.2.5 Lactate Production and the Acidification of the Tumor Microenvironment  
As described, much of the pyruvate generated by glycolysis in cancer cells is converted 
to lactate by lactate dehydrogenase (LDH).  At physiological pH, lactic acid exists primarily as a 
dissociated lactate anion and proton.  To prevent intracellular acidification and death, lactate is 
exported from the cell by a family of passive proton-lactate membrane symporters called the 
monocarboxylate transporters (MCTs).  Not surprisingly, MCTs, especially the MCT1 and MCT 
4 isoforms, are over-expressed in most cancers to facilitate the overload of lactate production 
that occurs with the Warburg effect [192, 193].  While the normal concentration of lactate in 
healthy tissue is approximately 2 mM, the median value of human tumors is 14 mM and can 
range up to 40mM [194-196].  Previously the excess production of lactate by cancers was 
considered simply to be a byproduct of the Warburg effect, but we now know that lactate 
mediates a considerable number of effects in the tumor, promoting growth, invasion, and 
metastasis [12].   
Lactate itself is an important signaling molecule, inducing the activity of over 650 genes 
involved in a wide variety of cellular functions, such as signal transduction, membrane transport, 
oxidative stress, growth, proliferation, and apoptosis [197].  Lactate is also considered to be a 
hypoxia mimetic, as it is able to activate HIF-1 in normoxic cancer cells, suggesting multiple 
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mechanisms by which lactate promotes tumor progression, invasion, and metastasis [106, 198, 
199].  Extracellular acidification promotes angiogenesis by inducing the expression of VEGF 
and IL-8, further facilitating tumor growth (99, 100).  The expression and function of the MCT 
proton/lactate symporters are largely dependent upon interaction with the extracellular 
membrane protein CD147 [200].  CD147 is also known as extracellular matrix metalloproteinase 
inducer (EMMPRIN), a name which reflects its important role in the remodeling of the 
extracellular matrix [201].  CD147 stimulates production of matrix metalloproteases (MMPs) by 
the tumor as well as stromal fibroblasts and endothelial cells [202].  These MMPs are activated 
by the low pH of the tumor microenvironment induced by lactate export [203].  Other 
modulators of the ECM are also activated by the acidic tumor microenvironment, including 
urokinase-type plasminogen activator and the cathepsins [204-210].  These enzymes degrade the 
basement membrane of the ECM, providing a pathway for invasion and metastasis.  The 
importance of lactate in tumor progression and analysis is further supported by in vivo studies in 
which inhibition of the MCT transporters and/or CD147 reduces tumor growth and invasion 
[202, 211-215].  Human tumors which are commonly associated with metastatic spread have 
higher lactate levels than non-metastatic tumors [194, 195, 216-218].  Considering this, it is not 
surprising that elevated lactate is clinically correlated to poor prognosis and a decrease in overall 
survival in a variety of cancers, including cervical, brain, head and neck, and lung [195, 216, 
217, 219-222]. 
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1.3.2.6 Oncogene and Tumor Suppressor Gene Interplay   
P53 is a well-characterized tumor suppressor that plays important roles in DNA damage 
and repair, and cell cycle control; however, its role in energy metabolism has only recently been 
characterized.  P53 stimulates aerobic respiration by activating the SCO2 gene which encodes 
the cytochrome c oxidase assembly protein and is thus required for assembly of the cytochrome c 
oxidase complex, an important component of the ETC [223].  Therefore, loss of p53, a common 
feature of many cancers, inhibits mitochondrial respiration [224].  This induces an increased 
reliance on fermentation for energy production, contributing to the Warburg effect.  Akt, also 
known as Protein kinase B (PKB), is a serine/threonine kinase and oncogene that stimulates 
proliferation and promotes cell survival by inhibiting apoptosis [225, 226].  Recently, it was 
shown that Akt enhances glucose uptake by inducing the translocation of the GLUT transporters 
to the plasma membrane [227].  It also activates hexokinase 2 (HK2), the first glycolytic enzyme 
which phosphorylates glucose to trap it in the cell, thus contributing to the Warburg effect.  
Overexpression of the oncogenic transcription factor c-Myc is also present in many different 
cancer types [228].  Myc activation promotes proliferation and assists in the maintenance of the 
stem-like phenotype [143, 229].  Myc contributes to aerobic glycolysis by binding to and 
activating nearly all of the glycolytic enzyme genes, including HK2, enolase, and lactate 
dehydrogenase A (LDHA) [230].  Furthermore, the acquisition of oncogenes and loss of tumor 
suppressors often activate HIF-1 which, as previously described, contributes to the Warburg 
effect through numerous mechanisms.  Oncogenes which stabilize HIF-1 include Src, Ras, PI3K, 
Akt, mTOR, EGFR, and HER2 [142, 231-235].  Similarly, loss of the PTEN, p53, and VHL 
tumor suppressors stabilize HIF-1 as well [232, 233, 236].     
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It has recently been discovered that mutations in metabolic enzymes alone, such as the 
Kreb’s cycle enzymes isocitrate dehydrogenase 1 (IDH1), fumarate hydratase (FH), and 
succinate dehydrogenase (SDH), are able to initiate tumors in vivo [237].  SDH mutations are 
common in gastric tumors, T-cell leukemia, and head and neck cancers [238, 239], while over 
70% of gliomas and glioblastomas contain IDH mutations [240, 241].  It is thought that the loss 
of some of these metabolic tumor suppressors is also due to their effects on HIF-1.  SDH and FH 
mutations cause an accumulation of succinate and fumarate which are structural analogs of α-
ketoglutarate (α-KG). Succinate and fumarate appear to mimic the effects of α-KG by inhibiting 
PHDs to activate the HIF-1 pathway [242, 243].  Furthermore, mutations in these metabolic 
enzymes would impair mitochondrial respiration and may have similar cancer promoting and 
metabolism altering effects as the aforementioned mitochondrial dysfunction.   
Interestingly, new evidence suggests that some oncogenes elicit their tumorigenic effects 
by mediating the Warburg effect.  V600EBRAF is a major driver mutation in the MAPK pathway 
of melanoma cells which induces proliferative signaling.  Hall and colleagues recently 
demonstrated that V600EBRAF also works to compensate for OXPHOS dysfunction by increasing 
glycolytic activity [244].  Although V600EBRAF activation sustains proliferative signaling 
through its effects on the MAPK pathway, this is not its critical function in melanoma.  Rather, 
oncogene addiction to V600EBRAF appears to be more fundamentally a glycolytic addiction as 
cellular senescence induced by V600EBRAF inhibition is rescued by overexpression of the 
glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [244].  Interestingly, 
the Warburg effect can also induce the activation of oncogenes.  Overexpression of GLUT3 in 
normal human breast cells activates a number of oncogenic pathways, including MAPK, Akt, 
EGFR, induces loss of apicobasal polarity, and enhances cell growth [245].   
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1.3.3 Metastasis and Cancer Metabolism 
The previous sections describing the causes and consequences of cancer metabolism 
illustrate how the dysregulated metabolic phenotype of cancer plays a critical role in every step 
of cancer progression, from tumorigenesis to invasion and metastasis.  Metastasis is considered 
the final phase of cancer development, and it is inarguably the most dangerous and least treatable 
aspect of the neoplastic phenotype.  Mitochondrial dysfunction, ROS production, tumor hypoxia, 
lactate production, and metabolically-mediated oncogene and tumor suppressor gene alterations 
all aid in the transition to a malignant phenotype.  Some researchers even hypothesize that the 
Warburg effect is primarily an adaptive mechanism to mediate acidification of the tumor 
microenvironment and allow for a primary tumor’s escape from the space limitations of the site 
of origin [246].  As described, the Warburg effect appears to be a prevalent and universal feature 
of metastatic tumors.  18F-FDG uptake and lactate production are both strongly correlated with 
metastasis and poor clinical outcome while mediators of cancer’s metabolic phenotype [12, 13, 
246], most notably HIF-1, regulate numerous players in EMT [20, 247].  The sheer prevalence of 
the Warburg effect in metastatic tumors demonstrate its importance in the malignant process and 
strongly suggests that therapies which exploit these metabolic pathways could offer new hope for 
the treatment of aggressive or late-stage cancers.   
 
1.4 Closing Remarks 
It is clear from a comprehensive review of the literature that cancer metabolism is a 
critical component of the neoplastic phenotype.  Recognition of the importance of these features 
provides insight into novel therapeutic targets aside from the classically-targeted genetic 
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mutations of cancer.  The ubiquitous nature of the Warburg effect in cancer, and the unique 
metabolic differences between healthy and cancer cells, have led to the suggestion that 
metabolism may provide a long-awaited Achilles’ heel to target therapeutically [248].  In the 
following chapter we will discuss three potential therapies which exploit cancer metabolism: the 
ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy.    
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CHAPTER 2: TARGETING CANCER METABOLISM WITH KETOSIS AND 
HYPERBARIC OXYGEN 
 
2.1 Chapter Synopsis 
Although the Warburg effect has been recognized for nearly a century, the field of cancer 
metabolism has received most of its interest and attention over the past decade.  The new 
information gained from these studies has revealed a multitude of novel therapeutic targets 
which exploit the dysregulated metabolic phenotype of cancer.  In this chapter, we provide a 
review of the literature and scientific rationale for three potential metabolic therapies – the 
ketogenic diet (KD), ketone supplementation, and hyperbaric oxygen therapy (HBOT).  The KD 
is a high fat, low carbohydrate diet that is hypothesized to inhibit cancer progression by 
restricting glucose availability to glycolysis-dependent tumors.  The KD also suppresses insulin 
signaling and flux through the pentose phosphate pathway, and inhibits ROS production and 
inflammation – all which could create an unfavorable environment for cancer.  Exogenous 
ketone supplementation as a cancer therapy is a novel idea that stems from the observation that 
the elevation of blood ketones induced by the KD may contribute to its efficacy.  It may also 
hinder cancer by its ability to inhibit glycolysis and ROS production, act as a histone deacetylase 
inhibitor, enhance mitochondrial health, and inhibit lactate export.  HBOT is the delivery of 
100% oxygen at elevated barometric pressure.  It has mostly been investigated clinically as a 
radiosensitizer, but has shown some efficacy as a stand-alone treatment in animal models, and 
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likely works by inhibiting angiogenesis and HIF-1 signaling, enhancing ROS production, and 
inducing mesenchymal-to-epithelial transition.  We hypothesize that these therapies would work 
individually and in combination to slow cancer progression and propose to test their effects on 
the VM-M3 model of metastatic cancer.  
 
2.2 Targeting Cancer Metabolism with the Ketogenic Diet 
Dietary interventions have been used to prevent and treat diseases for millennia.  Even 
when effective, however, dietary therapies are often overlooked or underappreciated in modern 
medicine [1].  An overwhelming collection of epidemiological studies now show a strong 
correlation between obesity, sedentary lifestyles, and the consumption of certain diets with 
lifetime risk of developing cancer [2-5].  Considering the Warburg effect, it is not surprising that 
many of these studies indicate sugar consumption and high glycemic index diets are correlated 
with an increased risk of developing a variety of cancer types [6-14].  An 8 year longitudinal 
study in middle aged Swedish men and women reported that consumption of sugar or high sugar 
foods, including soft drinks, sweetened fruit soups, or stewed fruits, was associated with a 
significantly increased risk of pancreatic cancer [14].  Data from a population-based case-control 
study revealed a significant correlation between high ratio of sucrose to dietary fiber intake and 
risk of colon cancer [8].  This increased risk was greatest in patients who were sedentary and/or 
had a high body mass index (BMI), leading authors to suggest that diets high in simple 
carbohydrates increase colon cancer risk in part by elevating blood glucose levels [8].  At least 
two large prospective studies demonstrated a significant correlation between the consumption of 
diets with a high glycemic index with an increased risk of breast cancer among overweight or 
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postmenopausal women [12, 13].  Similar to other cancer types, this risk was increased with 
limited physical activity or increased BMI [12, 13].  It is hypothesized that the frequent 
postprandial hyperglycemia and hyperinsulinemia caused by the consumption of high glycemic 
index diets play a causative role in this increased risk of cancer.  Indeed, an increase in glucose 
uptake by premalignant cells may also be sufficient to drive tumorigenesis in vitro.  Bissell et al 
reported that overexpression of glucose transporter type 3 (GLUT 3) in normal human breast 
cells  altered expression of the extracellular matrix mediator β1-integrin leading to a loss of cell 
polarity, and activated EGFR, MEK, and AKT oncogene signaling pathways leading to increased 
growth and proliferation [6].  It is not surprising, perhaps, that cancer continues to be very rare 
among hunter-gatherer societies which derive the majority of their calories from animal fat and 
protein, with only a small contribution from complex carbohydrates such as berries and roots 
[15, 16].  These observations, along with an increasing understanding of cancer metabolism, 
have prompted research into potential dietary therapies for the prevention and treatment of 
cancer.      
The ketogenic diet (KD) is a high fat, adequate protein, very low carbohydrate diet, 
classically consisting of a 4:1 macronutrient ratio of fats: protein + carbohydrate.  It is most well-
characterized clinically for its use in treating pediatric refractory epilepsy [17], but is proposed to 
have therapeutic efficacy for a variety of disorders, including obesity, diabetes, hypertension, 
Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, and Parkinson’s disease [18-20].  Like 
cancer, many of these diseases exhibit underlying metabolic pathology [21, 22] and chronic 
inflammation thought to be associated with a state of hyperglycemia [23-25].  The KD mimics a 
metabolic state of starvation, inducing a physiologic shift towards fat metabolism and a state of 
ketosis.  The carbohydrate restriction of the KD keeps glucose and insulin levels low, activating 
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gluconeogenesis, and forcing the acetyl CoA produced from fatty acid β-oxidation to be shunted 
towards ketogenesis in the liver.   
Decreasing circulating blood glucose with the KD is one method of exploiting the 
Warburg effect and is thought to selectively starve growing tumors of the glycolytic substrates 
which feed their rapid proliferation [26].  Although glucose deprivation was the original intent of 
using the KD as a cancer treatment, further investigation has uncovered many other mechanisms 
which may underlie the anti-cancer effects of this therapy.     
 
2.2.1 Literature Review  
The KD has been shown to slow cancer progression in a small number of animal and 
human studies for a variety of cancer types.   In the 23132/87 xenograft model of human gastric 
adenocarcinoma, a KD supplemented with medium chain triglycerides (MCTs) and omega-3 
fatty acids fed ad libitum significantly slowed tumor growth and increased survival time [27].  
Tumors in the KD-fed mice were less vascularized and had more necrotic areas than standard 
diet (SD) fed mice.   In in the LAPC-4 xenograft model of prostate cancer, the KD slowed tumor 
growth but did not increase survival time [28, 29].  However, in the LNCaP xenograft model of 
prostate cancer, the KD significantly prolonged survival [30].  Seyfried and colleagues have 
published many reports on the calorie restricted ketogenic diet (R-KD) as a therapy for brain 
cancer.  The R-KD decreased tumor weight when administered as a stand-alone therapy in the 
CT-2A malignant mouse astrocytoma model; however, it elicited potent synergistic anti-cancer 
effects when administered in conjunction with the glycolytic inhibitor 2-deoxy-D-glucose (2-
DG) [31].  In the same model, Seyfried et al showed that blood glucose levels had a direct and 
48 
 
positive correlation with tumor growth and that the R-KD significantly decreased plasma glucose 
[32].  The R-KD also decreased plasma insulin-like growth factor-1 (IGF-1) levels, a known 
biomarker for cancer progression and angiogenesis.  Similar results were demonstrated by 
Mukherjee et al wherein the R-KD decreased proliferation and vascularization and increased 
apoptosis in two prostate cancer models in vivo [33].  As was also observed by Seyfried’s group, 
calorie restriction of both a standard and KD elicited similar therapeutic effects in these models, 
suggesting that for some cancers total energy restriction may be a more important component of 
dietary therapy than macronutrient profile of the diet.  The KD has been evaluated in other brain 
tumor models as well.  Scheck and colleagues showed a significant synergistic response to the 
combination of KD and radiation therapy in the GL261 mouse model of glioma [34].  The KD 
fed ad libitum increased survival time by approximately 22%, but when administered 
concomitantly with radiation therapy, 82% of mice exhibited complete and permanent tumor 
remission, even after returning to a standard diet.  Similar synergistic effects were seen in two 
lung xenograft models, with the KD enhancing the efficacy of both radiation and carboplatin 
chemotherapy [35].    
The earliest report of using the KD as a cancer therapy in humans was published by 
Nebeling et al in 1995 [36].  This study was designed to determine if the KD could decrease 
glucose uptake by tumors in two female pediatric patients with late stage malignant 
astrocytomas.  Glucose uptake by FDG-PET imaging was decreased by an average of 21.8% in 
the two patients.  One patient responded remarkably well to dietary therapy, exhibiting clinical 
improvement in quality of life and motor function.  At the time of the report, she had continued 
the KD therapy for an additional year with no disease progression.  Zuccoli et al published a case 
report on a 65 year old woman with multicentric glioblastoma multiforme (GBM) treated with a 
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calorie-restricted ketogenic diet given concomitantly with standard care [37].  The patient 
responded well to dietary therapy, and after two months of treatment, her tumors were no longer 
visible by FDG-PET or MRI imaging.  Ten weeks after discontinuing the dietary therapy, 
however, her tumors returned and she eventually succumbed to the disease.  In recent years, a 
few small clinical trials have evaluated the effects of the KD on patients with late-stage, 
metastatic cancer.   In one such study, sixteen patients with advanced metastatic cancers were 
placed on a KD for 3 months and monitored for changes in quality of life and general health 
parameters [38].  The patients who completed the dietary regimen exhibited improvement in 
some factors pertaining to quality of life, such as better emotional functioning and decreased 
insomnia, with no significant adverse side effects.  Fine and colleagues recently reported the 
effects of what was described as an “insulin inhibiting” diet, but was essentially a very low 
carbohydrate ketogenic diet, in a group of 10 patients with advanced metastatic disease of a 
variety of tissue origins [39].  Although all patients had previously exhibited rapid disease 
progression, five of the nine patients who completed the study showed stable disease or partial 
remission during the 28 day dietary therapy.  A review of the literature strongly supports the 
potential use of the KD as an anti-cancer therapy; however, further validation in preclinical and 
clinical studies is needed to fully understand its use.   
 
2.2.2 Anti-Cancer Effects of the Ketogenic Diet  
2.2.2.1 Decreased Glucose and Insulin Signaling   
 Due to the Warburg effect, glucose from dietary carbohydrate provides the majority of 
metabolic fuel to most, if not all, cancers.  This observation prompted initial research into the 
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KD as a cancer therapy, with carbohydrate restriction-induced glucose deprivation widely 
regarded as the major mechanism by which the KD slows tumor progression.  It is well 
established that tumor growth is directly correlated with blood glucose levels and that 
hyperglycemia increases tumor growth rate in animals and in humans [32, 40, 41].  Glucose 
uptake is a rate-limiting step of glucose metabolism and is mediated by the glucose transporter 
(GLUT) proteins.  GLUT expression is consistently elevated in cancer cells of varying tissue 
origins [42].  Of the 14 known GLUT isoforms, GLUT 1 and GLUT 3 overexpression is most 
often associated with malignant transformation and progression, and both have been correlated to 
poor prognosis clinically [42].  The low Km of these enzymes allow tumors to import glucose 
from the blood even at relatively low plasma concentrations [43].  Excess glucose availability 
provides the glycolytic substrates to fuel the Warburg effect and all of its aforementioned 
beneficial consequences.  It also provides an energy substrate to support cellular functions 
despite the mitochondrial dysfunction which is so often associated with cancers [44].  Therefore, 
the KD is thought to work in large part by decreasing glucose availability to the tumor.  As 
described, the KD has been shown to decrease glucose uptake by tumors in humans [36].  Some 
studies suggest that the KD given in unrestricted amounts does not decrease blood glucose [27, 
32], while others reported a significant drop in glucose levels with the KD even when fed ad 
libitum [34, 45].  This variability is likely due to the individual heterogeneity of metabolism 
which is becoming increasingly more-well understood [46], as well as differences in the 
macronutrient sources in the respective KDs studied.     
Hyperglycemia stimulates insulin secretion from the pancreas.  High levels of circulating 
insulin, or hyperinsulinemia, is also associated with an increased risk of colorectal, pancreatic, 
and breast cancer, among others [47].  Hyperinsulinemia is closely related to obesity and 
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diabetes, both of which are known risk factors for cancer development.  However, studies 
suggest that hyperinsulinemia increases the risk of cancer mortality independently of diabetes, 
obesity, or metabolic syndrome [48, 49].  Insulin binds to the insulin receptor (IR) to mediate the 
cellular effects of glucose metabolism, but it also exerts a potent growth factor response.  IR 
expression and signaling is commonly over-activated in cancers and is considered to play an 
important role in promoting tumor growth and progression [50].  IR activation stimulates Ras 
and the MAPK cascade which mediate the mitogenic effects of insulin, promoting cell 
proliferation.  IR also works through the PI3K pathway to promote cell survival through Akt and 
mTOR.  Furthermore, Akt promotes expression of NFκB which activates pro-inflammatory and 
anti-apoptotic programs.  Growth promotion by insulin signaling cross-talks with the β-
catenin/Wnt pathway, and therefore may play a role in dedifferentiation and malignant 
progression [51].  Insulin also induces vascular endothelial growth factor (VEGF) expression, a 
potent activator of angiogenesis [52, 53].  Angiogenesis is required for tumor growth and plays a 
critical role in cancer progression and metastasis.  The KD decreases pancreatic insulin 
production by restricting carbohydrate intake.  It has also been shown to enhance insulin 
sensitivity in healthy tissues, which leads to decreased circulating insulin in the blood [54].  The 
KD has been reported to reduce vascularization in a xenograft model of gastric cancer, possibly 
through its inhibition of insulin signaling [27].  In a mouse model of prostate cancer, a reduction 
in tumor growth rate and prolonged survival was associated with a decrease in serum insulin in 
mice fed the KD [55].  In a small human trial, patients with end-stage cancer receiving a KD for 
28 days exhibited a significant drop in blood insulin [39].  This decrease in insulin was inversely 
correlated to the degree of relative ketosis, which was positively correlated to therapeutic 
response [39].  Therefore, the KD may work in part by inhibiting insulin signaling in tumors.   
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2.2.2.2 Reduced Flux through the Pentose Phosphate Pathway 
 A major consequence of the Warburg effect is increased flux through the pentose 
phosphate pathway (PPP).  As described, the PPP generates ribose-5-phosphate and NADPH, 
biosynthetic precursors necessary for nucleotide and lipid synthesis as well as endogenous 
antioxidant regeneration.   By decreasing glucose, the glycolytic substrate, the KD will decrease 
flux through the pentose phosphate pathway (PPP).  This will limit production of the anabolic 
substrates necessary for cell division and inhibit proliferation of the growing tumor.  Since the 
PPP also contributes reducing equivalents in the form of NADPH, up-regulation of this pathway 
provides a protective advantage to the cancer cell against radiation and chemotherapy insults 
which act through ROS-induced oxidative damage.  Intracellular levels of reduced glutathione 
(GSH) and ROS are tightly linked to regulation of cell death, suggesting that overstimulation of 
the PPP in cancer cells plays a role in evasion of apoptosis.  Thus, reducing flux through the PPP 
with the KD may also enhance the efficacy of standard care and sensitize the cancer cells to cell 
death.  Furthermore, two key enzymes of the PPP – glucose-6-phosphate dehydrogenase (G6PD) 
and transketolase-like 1 (TKTL) – are now widely accepted as oncogenes [56, 57], leading some 
to propose that dysregulation of the PPP should be considered a hallmark of cancer [58].  G6PD 
and TKTL are often overexpressed in cancer, and both are linked to tumorigenesis and cancer 
progression [56, 57].  The KD may also inhibit cancer progression by decreasing the activity of 
these two enzymes.       
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2.2.2.3 Influence on ROS Production and Redox Status 
There appears to be a significant differential effect of the KD on cancer versus normal 
tissue, possibly due to mitochondrial damage in the cancer cells.  In healthy tissues, the KD 
protects against oxidative stress by simultaneously decreasing ROS production and enhancing 
endogenous antioxidant capacity.  As described, the KD induces a physiological shift away from 
carbohydrate metabolism and towards fat and ketone metabolism.  Veech and colleagues studied 
the effects of ketone metabolism by investigating energy efficiency and mitochondrial 
respiration after administering a glucose-containing perfusate supplemented with 5mM βHB in a 
working rat heart [59].  Their studies showed that ketone metabolism increases the oxidation of 
co-enzyme Q in the electron transport chain, thus reducing production of the superoxide anion 
(O2
-∙), an important precursor for the generation of many ROS [59].  Ketone metabolism also 
caused a reduction of the mitochondrial NAD and cytoplasmic NADP couples which are 
necessary for regenerating reduced glutathione (GSH).  These effects appear to be ubiquitous and 
have been confirmed by studies in other tissues, most notably the brain.  βHB and AcAc decrease 
neuronal ROS production in vitro in response to glutamate [60] and prevent cell death in cortical 
slices following hydrogen peroxide (H2O2) exposure [61].  When fed for 3 weeks, the KD 
increased the ratio of reduced to oxidized glutathione (GSH:GSSG) in rat hippocampi, 
suggesting an improvement in antioxidant capacity [62].  These mechanisms likely underlie 
many of the well-known neuroprotective effects of the KD which have been reported in a 
number of pathologies, like Alzheimer’s disease, Parkinson’s disease, ALS, and epilepsy, among 
others [63].     
As described, the role of ROS in cancer is complex, with tumors benefitting from basally 
elevated ROS production yet sensitive to even modest changes in redox state [64].  
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Consequently, researchers are investigating both pro-oxidant and anti-oxidant treatments as 
potential cancer therapies.  Radiation and many chemotherapies work in large part by inducing 
ROS production while exogenous antioxidant supplements, such as vitamin C, are thought to 
work by quenching the ROS produced by tumors [65].  While the KD clearly elicits an 
antioxidant response in healthy tissues, its effects on cancer is unclear.  Scheck and colleagues 
showed that, similar to its effects in healthy brain tissue, the KD reduced ROS production and 
enhanced endogenous antioxidant expression in a mouse model of glioma [66].  Fath et al 
examined the effects of the KD, radiation, and carboplatin chemotherapy on oxidative stress in 
two lung cancer xenograft models [35].  They showed that the animals fed a KD in combination 
with radiation therapy exhibited increased lipid peroxidation and oxidative damage.  The 
differential effects of the KD on healthy versus cancer tissue remain to be elucidated but may 
depend in part on the tissue of origin and/or mitochondrial damage in the tumors [44].  Taken 
together, these studies suggest that the KD may work in part by increasing ROS production in 
the tumor while simultaneously protecting against oxidative stress in healthy tissues.  If this is 
the case, combining the KD with radiation or chemotherapy may enhance the efficacy of 
standard care while decreasing adverse side effects in patients.   
 
2.2.2.4 Inhibition of Inflammation 
 It is now widely accepted that chronic inflammation plays a critical role in tumorigenesis 
[67].  In their 2011 updated review, Hanahan and Weinberg added tumor promoting 
inflammation alongside genome instability and mutation as enabling characteristics which 
underlie the hallmarks of cancer [68].  Growing evidence suggests that up to 15% of all cancers 
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worldwide may be attributed to persistent infections [69].  Infiltrating immune cells mount an 
inflammatory response largely mediated by ROS which oxidize the nuclear genome of host cells.  
This DNA damage contributes to the accumulation of oncogene and tumor suppressor gene 
mutations which mediate malignant transformation.  Once a tumor forms, pro-inflammatory 
cytokines released from tumor itself and immune cells in the microenvironment foster a 
physiological niche which promotes cancer progression, invasion, and metastasis [67].  TNF-α, 
TGF-β, IL-6, IL-8, IL-10, CXCL1-3, and MIP-3 are some of the cytokines shown to mediate 
angiogenesis, tumor growth, invasion, and metastasis in a variety of cancers [67, 70].   
The KD may inhibit progression and induce cell death in cancers in part by inhibiting 
inflammation.  By comparing the effects of isocaloric high carbohydrate, low fat diet versus very 
low carbohydrate KDs, studies have shown that the KD reduces circulating inflammatory 
markers in humans [71].  In the study, patients on the KD exhibited decreases in numerous pro-
inflammatory cytokines, such as TNF-α, IL-6, IL-8, MCP-1, E-selectin, I-CAM, and PAI-1 [71].  
A similar study by the Volek lab showed a significant decrease in TNF-α, IL-6, C-reactive 
protein (CRP), and ICAM-1 following weight loss induced by the KD [72].  A study in guinea 
pigs showed that the KD reduced circulating levels of all of the 15 pro-inflammatory cytokines 
tested, including IL-1β, IL-2, IL-4, IL-7, IL-9, IL-12, IL-13, IL-15, IFN-γ, GM-CSF, and 
RANTES, among others [73].  Although the effect of the KD on inflammation in the tumor 
microenvironment remains largely untested, it is logical to hypothesize that its anti-inflammatory 
effects would persist there as well.  Therefore, the KD could inhibit cancer progression in part by 
reducing inflammatory signaling.  Furthermore, hyperglycemia is also known to be a major 
cause of chronic inflammation and oxidative stress [74].  This observation elucidates another link 
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between altered metabolism, tumorigenesis, and cancer progression as well as another 
mechanism by which the KD may inhibit tumor growth. 
 
2.2.3 Potential Concerns or Side Effects  
2.2.3.1 Variability in the Effects of the Ketogenic Diet  
 It is important to acknowledge that the scientific literature investigating the effects of the 
KD includes a wide variability in dietary design and therapeutic outcomes.  Some studies, 
especially in animals, have reported anti-cancer effects of the KD only when administered in 
calorie restricted amounts [32, 75, 76].  These studies have also indicated that if over-consumed, 
the KD can lead to hyperlipidemia and insulin insensitivity, and is not effective at lowering 
blood glucose [32, 77, 78].  Other studies in animals and humans have reported anti-cancer and 
other beneficial effects of the KD without significant adverse effects, even when consumed ad 
libitum [34, 45, 54, 66, 79-82].  It is possible that certain cancers will be more susceptible to KD 
therapy only when administered in calorically restricted amounts.  However, it is also very likely 
that variability in the macronutrient composition of the specific KD studied plays a significant 
role in these differential effects.  KDs that are well-balanced, such as those composed largely of 
ketogenic medium chain triglycerides, contain a healthy mixture of saturated and 
monounsaturated fats, and possess a low ratio of omega-6 to omega-3 polyunsaturated fatty acids 
(PUFAs), will likely provide more benefits with less adverse effects than unbalanced KDs, such 
as those composed almost entirely of lard or vegetable oil.  Furthermore, the appetite suppressing 
effects of the KD typically prevents overconsumption in humans, and is often unintentionally 
accompanied by calorie restriction which contributes to decreased blood glucose and other 
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beneficial effects [83, 84].  Therefore, it is important to recognize the caveats of these dietary 
studies and to use well-formulated KDs to evaluate new therapeutic potential.  
 
2.2.3.2 Cancer Cachexia and Weight Loss 
 Currently, very little information is provided to patients regarding optimal dietary 
guidelines following a cancer diagnosis.  Of the 21 National Comprehensive Cancer Network 
(NCCN) member institutions identified on www.nccn.org, only 4 of the institutions’ websites 
provide any nutritional guidelines for patients at all [85].  Rather than considering the effect of 
diet on cancer progression itself, the primary concern of diet for cancer patients clinically 
involves avoiding body weight loss associated with cancer cachexia.  As such, the most 
commonly recommended diets are low-fat, high-carbohydrate diets consisting of a 5:1 or 7:1 
ratio of carbohydrate to fat with high calorie intake [85].  Considering the effect of blood glucose 
on tumor growth, these dietary recommendations may be inadvertently promoting cancer 
progression.  However, the KD is a well-known weight loss tool for overweight individuals [86] 
and therefore it is important to consider its effects on body weight and muscle mass.   
 Cachexia is generally defined as weight loss and is characterized by loss of muscle mass, 
with or without loss of fat mass [87].  It is a consistent feature of late-stage cancer, with 86% of 
patients experiencing weight loss by the last 2 weeks of life [88].  While fat mass often 
decreases, the major detriment to health from cancer cachexia comes from loss of muscle mass.  
Up to 20% of cancer deaths are caused by cachexia-induced cardiac or respiratory failure [89].  
In fed conditions and while eating a high carbohydrate diet, the brain derives nearly all of its 
energy from glucose.  Glucose availability from glycogen stores are limited, however, and can 
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only satisfy the cerebral energy requirement for a short period of time without food before 
requiring additional glucose produced by gluconeogenesis of amino acids from muscle protein 
degradation [90].  If the brain was entirely reliant on glucose, starvation-induced muscle 
proteolysis would quickly interfere with cardiac and respiratory function and become fatal within 
2-3 weeks.  Therefore, the human brain evolved to metabolize ketones produced by the liver 
from stored fats during periods of calorie deprivation or starvation in order to spare muscle 
protein [90, 91].  This adaptation allows most adult humans to prolong survival during starvation 
to two or more months, depending on the amount of storage fat (triglycerides).  For this reason, 
ketones are considered to elicit a protein sparing effect [92].  While the KD promotes weight loss 
in obese individuals, it has been shown to prevent muscle loss during physical stress or energy 
restriction [93, 94].  Elevated blood ketones inhibit amino acid release from muscles as well as 
hepatic gluconeogenesis [95].  It makes sense that the KD would elicit similar protective effects 
against cancer cachexia.  Indeed, Fearon and colleagues reported that patients with late-stage 
cancer and cachexia fed a ketone-supplemented KD maintained a positive nitrogen balance and 
regained some of their lost weight [96].  In a mouse model of cachexia, animals fed the KD had 
smaller tumors but did not lose as much body weight compared to controls [97].  KD-fed animals 
also had lower levels of circulating catabolic factors, which stimulate lipolysis and proteolysis, 
than controls.  In similar studies, animals with colon cancer-induced cachexia showed a 
significant up-regulation of the ketone utilization enzyme 3-oxoacid CoA-transferase, suggesting 
a greater reliance on ketones for energy [98].  Supplying ketones to the body with the KD could 
support the health and metabolic needs of these tissues to withstand the physiologic stress of 
cachexia.  These studies indicate that the KD will not negatively affect body weight or muscle 
mass in cancer patients, but may actually prevent or reverse the cachexic phenotype.   
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2.2.3.3 Effects on Cardiovascular Health  
There is a common belief held by the medical and general populations that consuming 
large amounts of dietary fat is unhealthy and will lead to heart disease and increased mortality. 
Unfortunately, the history of nutritional science and guidelines is fraught with poor science and 
political interference [99].  Scientific evidence supporting the fat-heart hypothesis has always 
been controversial, and new, well-designed studies and meta-analyses of the literature are 
challenging the current dogma.  Recently, a systematic review and meta-analysis of over 75 
studies concluded that the current body of evidence does not support the common cardiovascular 
guidelines regarding fat consumption and found no significant correlation between risk of heart 
disease and fat intake [100].  In fact, isocaloric studies comparing low fat, high carbohydrate to 
well-formulated very low carbohydrate ketogenic diets (VLCKD) in humans show that the 
VLCKD improves biomarkers of cardiovascular health by decreasing body weight, decreasing 
trunk fat mass, improving body composition, decreased blood glucose and insulin, decreased 
blood triglycerides, and improved cholesterol ratio [79, 101-103].  In follow-up studies of 
children who followed the KD for several years to manage their retractable epilepsy, researchers 
found no significant long-term side effects associated with the diet [17, 104].  These studies 
suggest that there are no significant risks associated with the KD on cardiovascular or general 
health and can be considered a potential non-toxic therapy for cancer patients.   
 
2.3 Targeting Cancer Metabolism with Ketone Supplementation  
 Unlike normal tissues, many cancers do not seem capable of efficiently metabolizing 
ketone bodies for energy.  Cancer cells often lack expression of the ketone utilization enzymes, 
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like succinyl-coenzyme A:3-oxoacid coenzyme A transferase (SCOT) [105-108].  A study on 5 
different glioma cell lines concluded that glioma cells are unable to metabolize βHB to 
compensate for glucose restriction like healthy brain cells [109, 110].  Furthermore, as ketones 
are metabolized exclusively within the mitochondria, most tumors would have a reduced ability 
to use ketones for energy due to their dysfunctional mitochondria and impaired OXPHOS 
capability. 
The ketogenic diet, fasting, and calorie restriction are dietary regimens that have been 
shown to inhibit cancer progression in both preclinical and clinical studies [30, 36, 37, 39, 45, 
55, 111-113].  The generally accepted mechanism by which these therapies may work is by 
decreasing glucose availability to the tumor and suppressing the insulin and IGF signaling 
pathways.   However, all three of these therapies also induce a state of elevated blood ketones, or 
ketosis.  A recent study examined the effects of 28-day KD in patients with late-stage, metastatic 
cancers of a variety of tissue origins, including breast, fallopian tube, colorectal, lung, 
esophageal, ovarian, and lung [39].  All patients had prior progressive disease confirmed by 
FDG-PET upon beginning the dietary intervention.  After the one month treatment, over fifty 
percent of patients showed stable disease or partial remission.  Interestingly, there was no 
significant drop in blood glucose in the patients over the course of the diet.  Upon further 
analysis, the researchers determined that patient response was most strongly correlated with 
degree of relative ketosis from baseline.  This study was not the first, however, to hint at the anti-
cancer effects of ketones.  In 1979, Magee et al demonstrated that βHB inhibited proliferation in 
a dose dependent manner up to 20 mM in transformed lymphoblast, HeLa, and melanoma cell 
lines [114].  A more recent study showed that both AcAc and βHB inhibited viability and 
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induced apoptosis in neuroblastoma cells, but had no effect on control fibroblasts [105].  These 
observations strongly suggest that ketone bodies may possess inherent anti-cancer properties.  
 
2.3.1 Exogenous Ketone Supplementation 
Ketones are naturally produced in the body only under certain physiological conditions, 
including starvation, fasting, prolonged exercise, or during the consumption of a carbohydrate 
restricted ketogenic diet.  However, it is possible to elevate blood ketones artificially with 
sources of exogenous ketones or ketogenic agents.  These agents serve as ketogenic precursors 
and are either enzymatically cleaved or metabolized to produce ketones.  Thus, ketone 
supplementation can elevate blood ketone levels without the need for severe dietary restrictions.  
It is possible that exogenous ketone supplementation could provide many of the therapeutic 
effects associated with the KD without the need for severe dietary restriction.  It is also very 
likely that a ketone supplemented ketogenic diet would be easier to maintain and a more 
efficacious therapy than a standard KD or ketone supplementation alone.  1,3-butanediol (BD) 
and ketone esters are two sources of ketone supplements which can be administered to elevate 
blood ketones exogenously.   
 
2.3.1.1 1, 3-Butanediol 
  1, 3-Butanediol (BD) is an organic alcohol that was investigated in the 1950s as a calorie 
dense food for extended space travel [115].  After an adaptation period, BD contributes 
approximately 6 kcal/g of energy.  Extensive toxicology analyses indicate that BD is safe, with 
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very low acute and chronic toxicity and no teratogenic effects [115, 116].  Today it is FDA 
approved and most commonly used as a food flavoring solvent.  When orally administered, BD 
is metabolized by the liver to produce milimolar levels of βHB and can therefore be used as an 
exogenous source of ketone supplementation [117, 118].    
 
2.3.1.2 Ketone Esters  
In attempts to harness the therapeutic potential of the KD without severe dietary 
restrictions, researchers have developed synthetic ketone esters which are metabolized to the 
ketone bodies in vivo.  Birkhahn et al were the first to provide a practical method of 
administering large quantities of ketone bodies without sodium overload using a monoester of 
glycerol and AcAc [119-121].  Henri Brunengraber and Richard Veech have also developed a 
number of ketone esters which have been shown to elevate blood ketones in vivo [122-125], and 
toxicity studies indicate that these ketone esters are safe [126, 127].  The R, S-1, 3-butanediol 
acetoacetate diester (KE) is a nonionized, water-soluble precursor to ketone bodies designed by 
Dr. Dominic D’Agostino and created for our lab in collaboration with Patrick Arnold of Savind 
Inc.  Gastric esterases rapidly catalyze the release of AcAc, liberating R, S-1, 3-butanediol which 
is metabolized by the liver to produce βHB [128, 129].  Thus, the KD causes a rapid elevation in 
blood AcAc followed by a more sustained production of βHB. Single dose administration of the 
KE via intragastric gavage raised ketone levels to therapeutic levels (> 3mM βHB and >3 mM 
AcAc) in rats, and mimicked the anti-convulsant effects of the KD by increasing latency to 
oxygen toxicity-induced seizures [128].  Thus, the KE is a good source of exogenous ketone 
supplementation to investigate as a potential cancer therapeutic.    
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2.3.2 Anti-Cancer Effects of Ketone Supplementation  
2.3.2.1 Inhibition of Glycolysis 
 Ketone bodies are known to have a regulatory effect on glycolysis and glucose 
metabolism.  Early studies demonstrated that βHB inhibits glucose uptake by hearts of fed rats 
with normal glucose concentrations [130].  Furthermore, βHB inhibits the first and third 
enzymatic reactions of glycolysis, the phosphorylation of glucose by hexokinase and the 
phosphorylation of fructose-6-phosphate by phosphofructokinase [130].  In a study in fasted-
chick muscles, ketone bodies did not decrease glucose uptake but did significantly inhibit 
glycolysis and decrease intracellular pyruvate production [92].  Thus, ketone supplementation 
could directly inhibit the glycolytic enzymes of cancer cells which are heavily reliant on this 
metabolic pathway. 
 
2.3.2.2 Influence on ROS Production and Redox Status 
The effect of ketone supplementation on ROS and redox status in cancer versus healthy 
tissue would likely be very similar to the previously described effects of the KD (Section 
2.2.2.3).  Indeed, the antioxidant effects of the KD are largely attributed to ketone metabolism, 
which is known to decrease ROS production and increase endogenous antioxidant capacity in 
healthy cells [63, 95].  However, the inability of cancer cells to efficiently metabolize ketones for 
energy brings to question what effect ketones would have on redox state in tumors.  Electron 
transport is impeded in damaged mitochondria, causing them to produce more ROS than healthy 
mitochondria [64].  Ketone supplementation could potentially enhance this ROS production by 
shuttling more electrons through the ETC of damaged cancer mitochondria.  Dichloroacetate 
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(DCA) is a small molecule pyruvate mimetic that inhibits pyruvate dehydrogenase kinase, the 
inhibitor of pyruvate dehydrogenase complex, thus stimulating pyruvate conversion to acetyl 
CoA and entry into the Kreb’s cycle [131].  It is generally considered a stimulator of 
mitochondrial OXPHOS and is being investigated for its use as a cancer therapeutic.  DCA 
increases mitochondrial ROS production to a greater extent in cancer cells than healthy cells, and 
this discrepancy is tied to defects in mitochondrial ETC [131].  This observation supports the 
idea that shuttling energy metabolites through the ETC of dysfunctional mitochondria may 
damage cancer cells by increasing ROS production.  Ketone supplementation may impair cancer 
in this way.  Alternatively, ketone supplementation could elicit an antioxidant effect in cancer 
cells, similar to its effect in normal cells [60].  The response will likely be dependent on the 
degree of mitochondrial dysfunction in the particular tumor.  However, as cancers are susceptible 
to both pro-oxidant and anti-oxidant treatments, it is possible that either effect could provide 
therapeutic potential.   
 
2.3.2.3 Histone Deacetylase Inhibitor Activity  
The role of ketones as an energy metabolite has been long known; however, emerging 
evidence suggests that they have important functions as signaling molecules as well [132].  
Histone methylation and acetylation are major regulatory mechanisms which modulate DNA 
expression.  Cancers exhibit widespread differences in such epigenetic patterns compared to their 
normal tissue counterparts, allowing them to increase expression of oncogenes and inhibit the 
expression of tumor suppressor genes [133].  Histone deacetylases (HDACs) are a family of 
enzymes which catalyze the removal of acetyl groups from DNA histones and therefore play 
65 
 
critical roles in mediating these gene expression changes.  As such, histone deacetylase inhibitors 
(HDACI) have been investigated for their use as antineotplastic agents.  Preclinical evidence 
suggests that HDACIs may be efficacious in a number of malignancies, including acute myeloid 
leukemia (AML) and multiple myeloma (MM) [134, 135].  There are currently two HDACIs 
approved by the FDA for the treatment of T-cell lymphoma: vorinostat and romidpesin [136].  
HDACIs elicit a plethora of anti-cancer effects in vitro including inhibition of anti-apoptotic 
proteins, activation of pro-apoptotic proteins, induction of ROS generation and DNA damage, 
and inhibition of DNA repair [137].   
Verdin and colleagues recently demonstrated that βHB acts as an endogenous HDACI 
both in vitro and in vivo at milimolar levels easily achievable with the KD or ketone 
supplementation [138].  Many of the genes upregulated by βHB were involved in protection 
against oxidative stress, including Foxo3a, a transcription factor which induces cell-cycle arrest.  
It is possible that ketone supplementation could elicit similar effects as the pharmaceutical 
HDACIs in cancer cells.  Additionally, although histones were the first characterized targets of 
HDACIs, other non-histone proteins are also deacetylated by HDACs, including p53 and c-Myc 
[139].  This suggests that ketones could directly modulate the expression of important oncogenes 
and tumor suppressor genes.   
 
2.3.2.4 Enhancement of Mitochondrial Health and Function  
There is significant evidence to suggest that healthy mitochondria suppress the tumor 
phenotype.  As the name suggests, nuclear-cytoplasmic transfer studies involve the transfer of 
nuclei from one cell into the cytoplasm of another.  Several groups have investigated how tumor 
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cell nuclei behave when placed in cytoplasm from healthy cells, and vice versa.  Cybrid studies 
on melanoma cells indicated that the cytoplasm from healthy myoblasts suppressed their 
tumorigenicity in vitro [140].  Similarly, the cytoplasm from normal hepatocytes inhibited 
tumorigenicity of transformed hepatocytes, reducing in vivo tumor formation by 40% [141].  The 
same group showed in similar studies that while cybrids containing nuclei derived from 
malignant cells and cytoplasm from healthy cells formed tumors in only 17% of animals tested, 
cybrids containing cytoplasm from malignant cells and nuclei from healthy cells formed tumors 
in 97% of animals [142].  More recently developed techniques allow for the specific transfer of 
isolated mitochondria between cells.  These studies have demonstrated very similar effects.  
Mitochondrial transfer from normal mammary epithelial cells into a malignant osteosarcoma cell 
line restored respiratory function, inhibited proliferation and viability, induced pro-apoptotic 
signaling and sensitivity to chemotherapy, and inhibited invasive and colony formation 
properties in vitro [143].  These cybrids also showed reduced tumor growth in nude mice.  Many 
other nuclear-cytoplasmic or mitochondrial transfer studies have reported similar findings in a 
variety of cancer cell types [144-150].  Taken together, these studies strongly suggest that the 
mitochondria play a much more significant role in tumorigenesis than is currently acknowledged, 
and should be incorporated into the currently accepted theory which is decidedly genocentric 
[151].  It is also clear that healthy mitochondria can suppress the neoplastic phenotype, likely in 
part by maintaining ATP production which is critical for DNA repair and preservation of the 
integrity of the genome [152, 153].  Therefore, therapies which enhance mitochondrial health or 
function could prevent carcinogenesis and/or inhibit cancer progression.  Ketone metabolism is 
generally recognized to support mitochondrial health [95].  As described, ketones reduce 
mitochondrial ROS and enhance endogenous antioxidant defense mechanisms.  Therefore, they 
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can protect the mitochondrial membranes and genome from oxidative damage which impair 
respiratory and mitochondrial function.  Furthermore, Veech and colleagues have demonstrated 
that dietary ketone supplementation with a ketone ester induces mitochondrial biogenesis [125].  
Mitochondrial biogenesis in tumors with low mitochondrial numbers, as many exhibit, may 
restore some degree of normal mitochondrial function.  Indeed, mitochondrial amplification was 
shown to increase breast cancer chemosensitivity to doxorubicin [154], suggesting that 
mitochondrial biogenesis could also enhance the efficacy of standard care.  It is possible that 
ketone supplementation could inhibit cancer progression by enhancing mitochondrial biogenesis 
or improving mitochondrial health and function.   
 
2.3.2.5 Inhibition of Lactate Export 
Both lactate and the ketone bodies are transported across the plasma membrane by the 
MCT family of transporters [155].  As previously described, inhibiting lactate export from 
cancer cells has a negative effect on survival and proliferation [156].  βHB has been shown to 
inhibit lactate export from isolated rat hepatocytes in vitro [157].  It is possible that ketones may 
damage cancer cells by inhibiting lactate export through competitive inhibition of MCTs, 
subsequently inducing intracellular acidification and preventing the tumor promoting effects of 
lactate in the tumor microenvironment.     
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2.3.3 Potential Concerns or Side Effects 
2.3.3.1 Ketoacidosis and Effect on Blood pH 
Because of the macronutrient profile and calorie consumption of the standard Western 
diet, ketone bodies are not often detectable in the blood of healthy adults.  However, they make a 
dangerous appearance in patients with uncontrolled diabetes.  In diabetic ketoacidosis (DKA), 
high blood glucose levels and dysregulated insulin signaling induces unrestrained ketogenesis.  
Blood ketone levels may rise to the range of 20 – 25 mM.  Since ketones are acids, at these 
elevated levels, blood pH drops and can cause widespread organ failure.  If not properly 
administered, ketone supplementation has the potential to induce ketoacidosis.  However, we 
anticipate that ketone supplementation could inhibit cancer progression within a range of 
therapeutic ketosis (2 – 7 mM), levels far below the range at which blood pH is affected.       
 
2.4 Targeting Cancer Metabolism with Hyperbaric Oxygen Therapy  
Hyperbaric oxygen therapy (HBOT)  is a treatment in which patients breath 100% 
oxygen in a hyperbaric chamber which has been pressurized to greater than the barometric 
pressure of sea level, 1 atmosphere absolute (ATA).  HBOT can be administered in mono-place 
(single person) or multi-place (multi-person) chambers which are typically pressurized between 
2 to 3 ATA for 1.5 to 2 hours at a time [158].  While mono-place chambers can be pressurized 
with 100% oxygen, multi-place chambers are often pressurized with air while the patients inside 
breathe 100% oxygen through a mask or endotracheal tube.  The Undersea and Hyperbaric 
Medical Society (UHMS) has approved the use of HBOT for a variety of disorders, including 
decompression sickness, carbon monoxide poisoning, and radionecrosis among others [159].   
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The physiological basis of HBOT as a treatment modality is based on the gas laws.  
Dalton’s law states that in a mixed gas, each element exerts a pressure proportional to its partial 
pressure, or its fraction of the total volume.  Henry’s law states that the amount of gas dissolved 
in a liquid or tissue is proportional to the partial pressure of that gas in contact with the liquid or 
tissue.  While breathing air at atmospheric pressure, most of the oxygen carried through the 
blood is bound to hemoglobin.  In this situation, blood hemoglobin is working at nearly 
maximum capacity and is approximately 97% saturated with oxygen, with only a small amount 
of oxygen dissolved in the blood plasma compartment.  According to Dalton’s and Henry’s laws, 
by increasing the percent of oxygen breathed, or the pressure at which oxygen is breathed, more 
oxygen will dissolve into the blood plasma.  HBOT increases both the percent and pressure of 
oxygen breathed, supersaturating the blood with oxygen.  The increase in blood oxygenation 
following HBOT can be significant.  Breathing 100% oxygen at 3 ATA increases mean arterial 
oxygen tension from approximately 100 mm Hg to 2000 mm Hg and mean tissue oxygen tension 
from approximately 55 mm Hg to 500 mm Hg [160].   This level of HBO increases the amount 
of oxygen delivery to the tissues by 20-fold, permitting the provision of 60 mL of oxygen per 
liter of blood compared to the 3 mL/L which is delivered while breathing normobaric air [161].  
Supersaturating the blood with oxygen to this degree can adequately support the resting tissue 
oxygen requirement without a contribution from hemoglobin carriage, making HBO an ideal 
therapy for diseases in which hemoglobin function is impaired, such as anemia or carbon 
monoxide poisoning [162].  Because the excess oxygen is carried in solution, it can diffuse 
farther into the tissues to maximize tissue oxygenation, even spreading to areas where red blood 
cells cannot reach.   
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2.4.1 Literature Review  
The potential benefits of HBOT as a cancer therapy are clear.  Since tumor hypoxia 
promotes the cancer phenotype through several mechanisms, saturating solid tumors with HBOT 
may be able to reverse many of the cancer-promoting effects of hypoxia.  Indeed, HBOT has 
been shown to slow cancer progression in a variety of animal and human cancers.  
Comprehensive reviews on the topic conclude that overall, HBOT most often elicits a cancer-
inhibiting or neutral effect, with only a very small number of studies reporting a cancer-
promoting effect [163-165].   
There is significant variability in response between in vitro, in vivo, and clinical studies 
on HBOT and cancer, with multiple studies reporting positive or neutral responses in tumors of 
the same tissue of origin.  It is also sometimes found to only be effective when given as an 
adjuvant to radiation or chemotherapy, but not when administered alone.  Other studies report a 
positive effect of HBOT as a stand-alone treatment, suggesting the therapy efficacy may be 
highly tissue and context dependent.  Stuhr and colleagues have published several studies using 
clinically-relevant HBOT protocols which induced a significant inhibition on tumor growth in 
mouse models of breast cancer [166-169].    Two small studies in humans did not report an effect 
of HBOT on cancer progression or survival [170], but did report decreased pain, edema, and 
erythema following radiation breast-conserving surgery [171].  HBOT improved the outcome of 
patients with colorectal cancer when given as an adjuvant to radiation therapy [172], and animal 
studies suggest that it may only be effective when given as an adjuvant to radiation, 
photodynamic therapy, or chemotherapy for this cancer type [173, 174].  Gliomas appear to be a 
cancer type where HBOT may be effective to some degree as a stand-alone therapy.  Increasing 
pO2 in a rat xenograft model with both normobaric hyperoxia and low-level HBO reduced tumor 
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growth and vascular density [175].  However, it is quite possible the response could vary with an 
orthotopic implantation model.  Kohshi and colleagues reported that HBOT given as an adjuvant 
to radiotherapy in patients with malignant gliomas increased mean survival time from 12 to 24 
months compared to patients receiving radiotherapy alone [176].  Another study demonstrated 
that HBOT prolonged the biological residence time of the chemotherapy carboplatin in patients 
with malignant glioma [177].  In vitro studies showed that HBOT decreased proliferation, 
induces apoptosis, and sensitized prostate cancer cells to chemotherapy treatment [178, 179]; 
however, animal studies in models of prostate cancer found no significant effect [180-182].  In 
vitro studies have shown that HBOT induces apoptosis in several different leukemia cell lines 
[183, 184], suggesting it may be effective against this malignancy as well [185].  However, it has 
not been thoroughly investigated in animals or humans.  The studies described here represent 
some of the most recent work done investigating HBOT and cancer [164], but fifty years of prior 
studies suggest similar results [163].  There is a high variability in response to HBOT in 
preclinical and clinical studies, which is likely attributed to insufficient understanding of its 
mechanisms of action, failure to develop and test standardized protocols of treatment, lack of 
knowledge regarding its interactions as an adjuvant to standard care, and individual patient and 
tumor-type responses.  Clearly HBOT offers significant potential as a cancer treatment, but we 
must continue to study its effects in animal models to determine exactly when, where, and how it 
will be most beneficial clinically.     
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2.4.2 Anti-Cancer Effects of Hyperbaric Oxygen Therapy 
2.4.2.1 Inhibition of Angiogenesis 
As described, tumor hypoxia initiates a positive feedback cycle wherein the new, 
immature blood vessels formed promote further hypoxia and angiogenesis.  HBOT saturates 
tumors with oxygen, which can inhibit angiogenic signaling, limit new blood vessel formation, 
and prevent further tumor growth.  Many of these effects are likely due to inhibition of HIF-1, a 
potent enhancer of angiogenic activators like VEGF and PDGF.  Pigment epithelium derived 
factor (PEDF), an inhibitor of angiogenesis, is also stimulated by hyperoxia [186].  A small 
number of animal studies have demonstrated that HBOT can reduce angiogenesis and blood 
vessel density in vivo.  Stuhr et al reported that HBOT and normobaric hyperoxia decreased 
vascular density and tumor growth in DMBA-induced rat mammary tumors [166, 167].  Pro-
angiogenic genes including VEGFα, VEGFβ, FGF, PDGF, and TGF-α were down-regulated in 
HBOT-treated tumors.  Similarly, HBOT reduced both central and peripheral blood vessel 
density in rat glioma xenografts [175].   
 
2.4.2.2 Inhibition of HIF-1 Signaling  
HIF-1 activation is dependent on tissue pO2.  Its regulatory subunit, HIF-1α, is rapidly 
degraded under normal oxygen tension [187].  HBOT significantly increases intratumoral pO2 
[188].  Restoring normal oxygenation can potentially off-set the tumor-promoting effects of HIF-
1 signaling in the tumor.  The effects of HBOT on HIF-1α expression in cancer have not been 
well-investigated.  However, a number of studies in focal or global brain ischemia models 
indicate that HBOT decreases HIF-1α in the striatum, hippocampus, and cortex of rats [189, 
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190].  HBOT would likely elicit similar effects in hypoxic tumors.  HBOT down-regulated the 
expression of several HIF-responsive genes in a rat mammary tumor, but the authors did not 
report its effect on HIF-1α specifically [167].  As the downstream effects of HIF-1 activation are 
so widely implicated in cancer progression, invasion, and metastasis, it is important to 
characterize the effects of HBOT on this signaling cascade in neoplastic cells.  It is likely, 
however, that HBOT will inhibit HIF-1 expression in tumors as it does in healthy tissues.   
 
2.4.2.3 Enhanced ROS Production 
Breathing pure oxygen at greater than 1 ATA increases ROS production in the tissues 
[191].  D’Agostino and Dean demonstrated that HBOT elicits significant oxidative stress in U87 
glioma cells as shown by enhanced lipid peroxidation and plasma membrane blebbing measured 
with atomic force microscopy [192].  These effects were reduced with the antioxidant trolox-C, 
confirming that the lipid peroxidation was ROS-mediated.  Membrane blebbing is a consistent 
feature of apoptosis, suggesting that HBOT sensitized the U87 cells to cell death by the 
production of ROS [193].  Both intrinsic and extrinsic activation of apoptosis depend on ROS 
signaling [194].  Fas ligand (Fas-L) increases ROS production which serve as a necessary signal 
for recruitment of the Fas-associated death domain (FADD) and subsequent activation of the 
caspase cascade in the extrinsic pathway [195].  Similarly, ROS stabilize the mitochondria 
permeability transition pore allowing release of cytochrome c, the widely regarded point of no 
return for induction of the intrinsic apoptotic pathway [196]. 
It is important to note there appears to be a relative selectivity of pro-oxidant therapies in 
that levels which are cytotoxic to cancer cells are significantly less so to their normal tissue 
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counterparts [196].   We have seen similar results in our laboratory by comparing ROS 
production in healthy brain cells versus brain tumor cells following HBOT (unpublished data).  
This may be one consequence of the state of elevated ROS in which cancer cells exist.  
Comparing basal ROS production between oncogene-transformed and normal cells of the same 
cell type show a clear increase in ROS production following transformation [197, 198].  Wang 
and colleagues suggested that while cancers benefit from this elevation in ROS, this pushes them 
closer to, and thus more susceptible to, surpassing the threshold level which inevitably induces 
cell death [196].  Thus it is possible to incite cell death with even modest increases in oxidative 
stress [196].  Mitochondrial damage likely underlies the differential increase in ROS production 
between cancer and normal cells following pro-oxidant therapies like HBOT [64].  Increasing 
pO2 in tumor cells with faulty mitochondria could further increase the capture of electrons by 
molecular oxygen, leading to an exacerbated oxidative response.       
 
2.4.2.4 Induction of Mesenchymal-to-Epithelial Transition 
 As described, hypoxia and HIF-1 signaling mediate many components of the EMT, 
including TGF-β, Notch, SNAIL, SLUG, TWIST, and ZEB.  HBOT increases intratumoral 
oxygen tensions, suggesting that it would inhibit HIF-1 activity and consequently its downstream 
effectors.  Moen and colleagues investigated the effects of HBOT on EMT in a rat model of 
DMBA-induced mammary adenocarcinoma [167].  Tumors were allowed to grow for 5 weeks 
before treated rats received four 90-minute sessions of HBOT (100% O2, 2 bar) over a 10 day 
period.  While the tumors in control animals continued to grow significantly during the treatment 
period, tumors in HBOT-treated rats shrunk in size.  Tumors were excised and analyzed for 
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morphological, vascular, and gene expression changes.  HBOT-treated tumors had an increased 
expression of epithelial markers, including AREG, KRT14, KRT5, CDH1, PERP, DSP, SerpinB, 
ODN, and CDH3.  The mesenchymal markers SNAIL2, FGFR1, CDH2, fibronectin-1, CDH11, 
S100α4, BMP-7, FZD2, TWIST2, NID1, and vimentin were significantly down-regulated.  This 
study clearly demonstrates the potential for HBOT to reverse and inhibit the EMT phenotype and 
suggests that it may be effective at preventing or treating metastatic disease.     
 
2.4.3 Potential Concerns or Side Effects   
2.4.3.1 Stimulating Angiogenesis 
HBOT is used clinically to promote the healing of chronic wounds [199].  Because one of 
the major mechanisms by which HBOT enhances wound healing is through the stimulation of 
angiogenic signaling, early studies predicted that it would elicit similar effects in cancer [200].  
Interestingly, and for reasons not well-understood, decades of research since have shown that 
HBOT actually elicits opposite effects in wounds and tumors [201].  Feldmeier and colleagues 
proposed potential contributing factors for the differential response to HBOT between wounds 
and tumors: (1) wounds involve negative space while tumors grow in limited physical space, (2) 
tumors are largely unresponsive to negative feedback signals from nearby tissues while wounds 
respond appropriately, and (3) tumors form abnormal vasculature with chaotic blood flow while 
wounds regrow normal, functional blood vessels [201].  Any or all of these characteristics may 
contribute in part to the poorly understood differential effects of HBOT on angiogenesis in 
wounds and tumors.   
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2.4.3.2 Soft Tissue Radionecrosis 
 Clinical studies suggest that when administered concurrently with radiation, HBOT can 
improve response to therapy, but may also enhance soft tissue necrosis in surrounding normal 
tissue [202].  However, Kohshi and colleagues demonstrated that these adverse effects can be 
ameliorated by administering HBOT immediately prior to, not concurrent with, radiotherapy 
[176]. 
 
2.5 VM-M3 Model of Metastatic Cancer 
Metastasis is responsible for over 90% of cancer-related deaths [203].  Extent of 
metastatic spread is the best predictor of clinical outcome, with patient prognosis worsening 
significantly once a primary tumor has spread to distal tissues.  For example, while the 5-year 
survival rate for stage 1 breast cancer is 98%, it drops to 16-20% in metastatic breast cancer 
patients [204].  Currently, there are very few treatments effective for long-term management of 
metastatic disease.  Radiation and many chemotherapies are often successful at shrinking 
primary and metastatic tumors initially, but some portion of cancer cells often survive initial 
treatment.  They exist in a dormant state as minimal residual disease for some period of time 
before re-emerging and re-establishing tumor foci.  These recurrent tumors are often very 
resistant to further treatment and account for the majority of cancer deaths.  Perhaps one of the 
biggest obstacles preventing the development of permanently effective treatments for metastatic 
disease is the lack of preclinical models which reflect the metastatic behavior of malignant 
human tumors.  Xenograft models involve the implantation of human cancer cells in 
immunodeficient rodents and are commonly used in preclinical research.  However, these tumors 
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often do not metastasize, even when created from highly aggressive cancers.  The immune 
system is known to play a critical role in cancer progression and metastasis.  Thus, perhaps it is 
not surprising that many therapies that are effective in xenograft models provide little to no 
therapeutic efficacy in human clinical trials.  Transgene or carcinogen-induced models are also 
used, but typically only form metastases in a portion of animals.  It is also unclear how similar 
the tumorigenic pathology of these models are to spontaneous tumors.  Tail-vein injection 
models often form metastatic lesions but eliminate some of the most critical aspects of metastatic 
spread including escape from the confines of the primary tumor and intravasation into the 
vasculature.     
The VM-M3 model of metastatic cancer was developed from a spontaneous brain tumor 
in a mouse of the VM/dk inbred strain by Dr. Thomas Seyfried of Boston College [205].  VM/dk 
mice have an unusually high incidence (approximately 1.5%) of spontaneous brain tumors [206, 
207].  This is approximately a 210-fold increase in incidence compared to C57BL/6J mice [208].  
Most of the spontaneous tumors in VM/dk mice are characterized as astrocytomas [206, 207].  
VM/dk mouse brains have abnormal mitochondrial phospholipid composition and altered 
activity of the ETC complexes compared to C57BL/6J mice, characteristics which have been 
proposed as a potential explanation for their unique propensity for brain tumors [208].  As 
previously described, abnormalities in mitochondrial lipids and ETC complex function is a very 
common feature of human cancers.  The VM-M3 tumor was adapted to cell culture and 
transduced with a lentivirus vector containing firefly luciferase under control of the 
cytomegalovirus promoter allowing for in vivo bioluminescent imaging [205].  VM-M3 cells are 
highly invasive and metastatic in vivo.  Intracerebral implantation induces the formation of a 
malignant brain tumor that behaves remarkably similar to human glioblastoma multiforme 
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(GBM).  VM-M3 cells invade both the ipsilateral and contralateral hemispheres, and migrate 
through the CNS via the Secondary Structures of Scherer, the unique pattern of human GBM 
invasion described by Hans Scherer in the 1940s [209].  Some animals even exhibit extraneural 
metastases from orthotopic implantation.  It is commonly thought that primary brain tumors 
cannot metastasize outside the CNS, but this should be reevaluated based on a significant amount 
of clinical data that suggests otherwise.  Indeed, numerous case reports have confirmed 
secondary metastatic GBM lesions in the peripheral tissues in humans [210-219].  One report 
even described the rapid development of metastatic cancer of GBM origin in multiple transplant 
recipients who received organs from a patient who died of a primary GBM [220].  A review of 
the literature clearly demonstrates that primary brain cancer can form systemic metastases if they 
gain access to extracranial sites.  Considering the poor prognosis of malignant brain cancer, it is 
thus likely that most patients simply die of primary tumor burden prior to extraneural metastasis 
or before metastatic lesions become symptomatic.  Thus, the metastatic behavior of VM-M3 
cells represents another characteristic of human disease and further supports its use as a 
preclinical model of malignant cancer.  The remarkable metastatic potential of VM-M3 cells led 
Seyfried and his team to create the VM-M3 model of metastatic cancer.  Subcutaneous 
implantation of VM-M3 cells results in rapid and systemic metastasis within approximately 2-3 
weeks that is highly reproducible [205].  Primary sites of metastasis include liver, lungs, kidney, 
spleen, adipose, intestine, bone marrow, and brain.   
In culture, VM-M3 cells exist in a mixed morphology of large flat cells with 
protoplasmic extensions and small, rounded cells which coordinate with cell cycle progression 
[205].  The large, flat cells transform into the rounded cells for division, and return to their prior 
morphology after mitotic completion.  VM-M3 cells, like many malignant cells of various cancer 
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types, exhibit multiple molecular and behavioral characteristics of mesenchymally-derived 
macrophages [221-227].  As previously described, the remarkable similarities between metastatic 
cells and macrophages has led some researchers to hypothesize that macrophage transformation 
or tumor-macrophage fusion in the tumor microenvironment may play a pivotal role in 
metastasis [221, 225-231].  VM-M3 cells are highly adhesive as well as phagocytotic, as 
demonstrated by their ability to uptake fluorescent beads in culture.  They express high levels of 
the CXCR4 chemokine receptor, which is considered to be a marker for highly invasive GBM as 
well as microglia/macrophages [205].  They also express many other cell surface markers of 
microglia/macrophages, including Iba1, CD11b, F4/80, CD68, and CD45 and have a lipid 
composition profile closely resembling macrophages as well [205].   
VM-M3 cells transformed spontaneously in vivo, and they are grown in 
immunocompetent VM/dk hosts with their syngeneic genetic background.  VM-M3 cells spread 
naturally from the s.c. adipose, thus replicating all of the major steps of metastasis, from 
escaping the confines of the site of inoculation to the establishment of metastatic lesions in distal 
organs.  Like most metastatic cancers, but unlike most cancer models, VM-M3 cells are 
exceptionally aggressive and difficult to kill in vitro and in vivo.  These factors likely account for 
their remarkable molecular and behavioral similarities with human disease and make the VM-M3 
model a very good choice for preclinical investigation of novel therapeutics.   
 
2.6 Central Hypothesis and Project Aims 
The metabolic abnormalities of cancer cells provide a plethora of therapeutic targets that 
have been largely unrealized to date.  As described, there is substantial scientific rationale for 
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investigating the anti-cancer efficacy of the KD, ketone supplementation, and HBOT.  The 
metabolic defects targeted by these non-toxic therapies are largely universal between cancer 
types, and are especially prominent in metastatic lesions.  As metastasis is the cause of nearly all 
cancer-related deaths, it is critically important to test the efficacy of novel therapies on 
preclinical models which exhibit metastatic behavior.  The KD and HBOT have been 
investigated to a limited extent in primary cancer models, and this preliminary evidence suggests 
a substantial need for further investigation.  Furthermore, the effect of the KD and HBOT on 
aggressive or metastatic cancer is largely unknown.  Ketone supplementation is a novel treatment 
that may inhibit cancer progression and metastasis in a variety of ways but has not been tested 
for its therapeutic efficacy.  We hypothesize that ketosis and hyperbaric oxygen metabolic 
therapies will elicit anti-cancer effects in the VM-M3 model of metastatic cancer when 
administered individually and as a multi-combination treatment.  The major goals of this 
research project were to characterize the effects of ketosis and HBOT on tumor growth, 
metastatic spread, and survival in VM-M3 mice in vivo, to corroborate their effects on VM-M3 
cells in vitro, and to provide preliminary insight into the cellular and molecular effects of these 
therapies for future mechanistic studies.  If effective, these treatments could provide novel, non-
toxic adjuvant treatments for many cancer patients, including those with aggressive or late-stage 
cancers who currently have very few therapeutic options.     
 
2.7 Closing Remarks 
 In this chapter we have provided a review of the literature and scientific rationale for 
three potential metabolic therapies for cancer: the ketogenic diet, ketone supplementation, and 
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hyperbaric oxygen therapy.  We hypothesize that these therapies will be effective treatments for 
many cancers and propose to test their efficacy in the VM-M3 model of metastatic cancer.  
Chapters 3-5 will consist of the results and a detailed discussion of this dissertation work.  A 
summary of the findings, closing remarks, and major implications of this data on cancer therapy 
will be discussed in Chapter 6.   
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CHAPTER 3: THE KETOGENIC DIET AND HYPERBARIC OXYGEN INHIBIT      
VM-M3 CANCER IN VITRO AND IN VIVO 
 
3.1 Chapter Synopsis 
In this chapter we present data demonstrating the effects of the KD and HBOT on VM-
M3 cancer in vitro and in vivo.  Both therapies elicited a trend of reduced tumor growth and 
metastatic spread in vivo, but only the KD, not HBOT, prolonged survival when administered as 
a stand-alone therapy.  However, combining the KD with HBOT resulted in a synergistic effect, 
increasing mean survival time by 78% compared to controls.  HBOT treatment decreased HIF-1α 
in vitro, an effect which likely contributes significantly to its use as a cancer therapy.  
Portions of this chapter have been previously published in “Poff A, Ari C, Seyfried T, 
D’Agostino D. (2013) The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in 
Mice with Systemic Metastatic Cancer. PLOS One” and a copy of this article may be found in 
Appendix C.  See Appendix B for copyright permissions.  Materials and methods for the studies 
presented in this chapter can be found in Appendix A.   
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3.2 The Ketogenic Diet and Hyperbaric Oxygen Inhibit VM-M3 Cancer in Vitro and          
in Vivo 
 As described, the KD and HBOT are two potential therapies which can be used to exploit 
the metabolic deficiencies of cancer cells.  In normal tissues, decreased oxygen availability 
inhibits mitochondrial production of ATP, stimulating an up-regulation of glycolytic enzymes to 
meet energy needs by substrate level phosphorylation production of ATP.  Thus, the cellular 
response to tumor hypoxia is mediated by several of the same pathways that are overly active in 
cancer cells with mitochondrial damage and high rates of aerobic glycolysis.  This suggests that 
the ketogenic diet and HBO2T could target several overlapping pathways and tumorigenic 
behaviors of cancer cells.   We hypothesized that these treatments would work individually and 
synergistically to inhibit tumor progression.  We suggest that the addition of these non-toxic 
adjuvant therapies to the current standard of care may improve progression free survival in 
patients with advanced metastatic disease.   
 
 
Figure 3.1.  The KD and HBOT increases survival time in mice with systemic metastatic 
cancer. (A) Kaplan-Meier survival plot of study groups.  Animals receiving KD and KD+HBOT 
showed significantly longer survival compared to control animals (p=0.0194 and p=0.0035, 
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respectively; Kaplan-Meier and LogRank Tests for survival distribution).  (B) Treatment group 
cohort size and mean survival times shown.  KD mice exhibited a 56.7% increase in mean 
survival time compared to controls (p=0.0044; two-tailed student’s t-test); KD+HBOT mice 
exhibited a 77.9% increase in mean survival time compared to controls (p=0.0050; two-tailed 
student’s t-test).  Results were considered significant when p<0.05.  
 
Figure 3.2. Tumor bioluminescence in mice.  Tumor growth was slower in mice fed the KD 
than in mice fed the SD. (A) Representative animals from each treatment group demonstrating 
tumor bioluminescence at day 21 after tumor cell inoculation.  Treated animals showed less 
bioluminescence than controls with KD+HBOT mice exhibiting a profound decrease in tumor 
bioluminescence compared to all groups.  (B) Total body bioluminescence was measured weekly 
as a measure of tumor size; error bars represent ±SEM.  KD+HBOT mice exhibited significantly 
less tumor bioluminescence than control animals at week 3 (p=0.0062; two-tailed student’s t-
test) and an overall trend of notably slower tumor growth than controls and other treated animals 
throughout the study.  (C,D) Day 21 ex vivo organ bioluminescence of SD and KD+HBOT 
animals (N=8) demonstrated a trend of reduced metastatic tumor burden in animals receiving the 
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combined therapy.  Spleen bioluminescence was significantly decreased in KD+HBOT mice 
(*p=0.0266; two-tailed student’s t-test).  Results were considered significant when p<0.05. 
 
Figure 3.3.  Effect of KD, HBOT, and KD+HBOT treatment on metastatic spread in VM-
M3 mice.  In vivo bioluminescent imaging of key metastatic regions in VM-M3 mice 21 days 
post tumor cell inoculation was performed as an indicator of metastatic tumor size and spread.  
KD, HBOT, and KD+HBOT treated mice exhibited a trend of reduced spread to the brain, lungs, 
and liver, but these differences were not significant from controls (p>0.05; One-way ANOVA).  
Error bars represent ±SEM.  
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Figure 3.4. Blood glucose and β-hydroxybutyrate levels in animals.  (A) KD-fed mice 
showed lower blood glucose than controls on day 7 (***p<0.001).  Animals in the KD study 
group had significantly lower blood glucose levels than controls on day 14 (*p<0.05).  (B) 
KD+HBOT mice had significantly higher blood ketones than controls on day 7 (***p<0.001).  
Error bars represent ±SEM.  Blood analysis was performed with One Way ANOVA with 
Kruksal Wallis Test and Dunn’s Multiple Comparison Test post hoc; results were considered 
significant when p<0.05. 
 
 
Figure 3.5.  Animal Weight.  Body weight was measured twice a week.  Graph indicates 
average percent of initial body weight animals at days 7 and 14.  KD and KD+HBOT mice lost 
approximately 10% of their body weight by day 7 and exhibited a significant difference in 
percent body weight change compared to control animals (*p<0.05; ***p<0.001).  Error bars 
represent ±SEM.   
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Figure 3.6.  Glucose and weight change are correlated to survival.  Linear regression analysis 
revealed a significant correlation between day 7 blood glucose and percent body weight change 
with survival (p=0.0189 and p=0.0001, respectively).  Results were considered significant when 
p<0.05. 
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Figure 3.7. Effect of KD+HBOT treatment on metastatic liver tumor size and 
vascularization.  Morphology and vascularization of KD+HBOT-treated mouse liver tumors 
were analyzed by H&E staining and CD31 immunohistochemistry.  In general, tumors from 
KD+HBOT treated mice were smaller with more well-defined borders (A, C) and exhibited a 
trend of reduced vascularization (B, D, E) that was not significantly different from controls 
(p>0.05; unpaired t-test).  Error bars represent ±SEM.   
 
 
Figure 3.8. HBOT inhibits HIF-1α expression and enhances pAkt expression in VM-M3 
cells.  Expression of cancer and metabolic signaling molecules in VM-M3 cells grown in control 
media with or without 7 consecutive daily HBOT sessions (100% O2, 2.5 ATA, 90 min) was 
investigated by western blot analysis.  HBOT-treated cells expressed significantly less HIF-1α 
than cells grown in control media without HBOT (***p<0.001; unpaired t-test).  There was a 
trend of increased pAkt expression in HBOT-treated cells, but it was not significantly different 
from controls (p=0.29; unpaired t-test).  There was no effect of treatment on p44 MAPK/Erk1, 
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p42 MAPK/Erk 2, or phospho-mTOR (data not shown).  Error bars represent ±SEM.  Results 
were considered significant when p<0.05.  
 
The ketogenic diet and hyperbaric oxygen inhibit VM-M3 cancer in vitro and in vivo  
Nearly a century after Otto Warburg reported the abnormal energy metabolism of cancer 
cells, renewed interest in the field has elucidated a plethora of novel therapeutic targets.  Two 
promising treatments involve the use of HBOT to reverse the cancer-promoting effects of tumor 
hypoxia and the use of the KD to limit the availability of glycolytic substrates to glucose-
addicted cancer cells.  Both therapies have been previously reported to possess anti-cancer 
effects [1-4].  Since these treatments are believed to work by targeting several overlapping 
mechanisms, we hypothesized that combining these non-toxic treatments would provide a 
powerful, synergistic anti-cancer effect.  Furthermore, since metastasis is responsible for the 
overwhelming majority of cancer-related deaths, we tested the efficacy of these conjoined 
therapies on the VM-M3 mouse model of metastatic cancer [5, 6].   
We found that the KD fed ad libitum significantly increased mean survival time in mice 
with metastatic cancer (p=0.0194; Figure 3.1).  It is important to note that KD-fed animals lost 
approximately 10% of their body weight over the course of the study (Figure 3.5).  It is well 
established that low carbohydrate, high fat ketogenic diets can cause body weight loss in 
overweight humans [7-9].  Ketogenic diets are also known to have an appetite suppressing effect 
which may contribute to body weight loss [10].  Along with appetite suppression, a potential 
contributing factor to the observed body weight loss is the possibility that mice found the KD to 
be less palatable and were self-restricting caloric intake.  As calorie restriction is known to elicit 
 104 
 
profound anti-cancer effects, the ketogenic diet may inhibit cancer progression in part by indirect 
dietary energy restriction [11, 12].  Fine and colleagues recently used a very low carbohydrate 
KD to promote stable disease or partial remission in patients with advanced metastatic cancer 
[13].  Fine’s study demonstrated a correlation between blood ketones and response to the diet 
therapy, suggesting that ketone elevation itself also contributes to the anti-cancer efficacy of the 
KD.   
HBOT inhibited HIF-1α expression in VM-M3 cells (Figure 3.8).  As described, the 
activity of the HIF-1 transcription factor plays an important role in every aspect of cancer 
progression, from tumorigenesis to metastasis [14, 15].  Inhibition of HIF-1α, and subsequent 
inhibition of HIF-1 activity, by HBOT in VM-M3 cells likely plays an important role in its anti-
cancer efficacy both in vitro and in vivo.  Although not statistically significant, pAkt expression 
may be slightly enhanced by HBOT.  Oxidative stress and HBOT are both known to activate Akt 
signaling in normal cells [4, 16].  It is likely that HBOT induced oxidative stress in VM-M3 cells 
is responsible for the elevation in pAkt expression observed.  Furthermore, in humans, HBOT 
decreases blood glucose immediately following treatment [17].  There is some evidence to 
suggest this is caused by improved insulin sensitivity which may be mediated in part by the 
PI3K/Akt pathway [18] and thus could contribute to the elevation in pAkt expression following 
HBOT in the VM-M3 cells.     
Although not significant from controls, there was a clear trend of reduced metastatic 
spread in KD, HBOT, and KD+HBOT treated mice as measured by in vivo bioluminescence 
imaging of key metastatic regions (Figures 3.2 and 3.3).  Tumors from KD+HBOT treated mice 
were smaller and appeared to have more well-defined borders by morphological analysis, and 
exhibited a trend of decreased vascularization compared to tumors from control mice (Figure 
 105 
 
3.7).  As tumors need to form new blood vessels to grow in size, the decreased vascularization 
observed in these tumors may play a role in preventing metastatic tumor growth.  Additionally, 
the tumors may be less vascularized because they are smaller than tumors from control mice at 
this time point.  Since HIF-1 signaling stimulates both angiogenesis and tumor growth, it is likely 
that HBOT-induced inhibition of HIF-1 is contributing to both of these effects in vivo.  These 
observations clearly support that ketosis and HBOT elicit anti-cancer effects in vivo, even when 
tested in an aggressive model of metastatic cancer.       
As hypothesized, profound anti-cancer effects were observed in our metastatic mouse 
model after combining the KD with HBOT.  Combining these therapies nearly doubled survival 
time in mice with metastatic cancer, increasing mean survival time by 24 days compared to 
control animals (p=0.0050; Figure 3.1).  The KD+HBOT-treated mice exhibited significantly 
decreased bioluminescence compared to controls at week 3 (p=0.0062) and a trend of decreased 
tumor growth rate throughout the study (Figure 3.2).  By day 7, all animals on a ketogenic diet 
had significantly lower blood glucose levels than controls (Figure 3.4).  As it has been shown 
that tumor growth is directly correlated to blood glucose levels [19], this decrease in blood 
glucose concentration likely contributed to the trend of decreased tumor bioluminescence and 
rate of tumor growth seen in KD-fed animals (Figure 3.2).  Nebeling et al. demonstrated that the 
KD significantly decreased glucose uptake in pediatric brain tumor patients by FDG-PET 
analysis [20].  This clinical data suggests decreased glucose delivery to the tumor is a causal 
mechanism in KD treatment.  All KD-fed mice showed a trend of elevated blood ketones 
throughout the study; however, only KD+HBOT mice had significantly higher ketones than 
controls on day 7 (Figure 3.4).  As ketones are metabolized exclusively within the mitochondria, 
cancer cells with damaged mitochondria are unable to adequately use them for energy.  Many 
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cancers do not express the Succinyl-CoA: 3-ketoacid CoA-Transferase (SCOT) enzyme which is 
required for ketone body metabolism [21, 22].   In fact, βHB administration prevents healthy 
hippocampal neurons but not glioma cells from glucose withdrawal-induced cell death [23].  
Furthermore, ketone bodies have anti-cancer effects themselves, possibly through inhibition of 
glycolytic enzymes [24].  Skinner and colleagues demonstrated that acetoacetate and βHB 
administration inhibits brain cancer cell viability in vitro [25].  Thus, the elevated ketone levels 
in the KD+HBOT mice likely enhanced the efficacy of this combined therapy.     
Potential concern may arise regarding the use of a diet therapy for cancer patients 
susceptible to cachexia.  While low carbohydrate or ketogenic diets promote weight loss in 
overweight individuals, they are also known to spare muscle wasting during conditions of energy 
restriction and starvation [26-29].  In an animal model of cancer cachexia, administration of a 
low carbohydrate, high fat diet prevented weight loss of the animals while simultaneously 
decreasing tumor size [30].   Similar effects were described in human cancer patients [20, 31].  
The anti-cachexia effects of the KD are not surprising when considering a metabolic switch to fat 
metabolism and subsequent ketosis evolved as a method of sparing protein during prolonged 
fasting or starvation [26, 32, 33].  It makes sense that dietary-induced therapeutic ketosis in a 
cancer patient would prevent muscle wasting similarly as it does with athletes undergoing intense 
exercise [34].  Furthermore, when given as an adjuvant treatment to advanced cancer patients, 
the KD improves quality of life and enhances the efficacy of chemotherapy treatment in the 
clinic [35, 36].  This and other emerging evidence calls into question the common medical advice 
of limiting fat consumption in overweight cancer patients [37].   
Veech and colleagues described the mechanisms by which ketone metabolism protects 
cells from oxidative damage [28, 32], while more recent evidence suggests that ketones function 
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as HDAC inhibitors [38].  βHB metabolism results in an increased reduction of the NAD couple 
and increased oxidation of the co-enzyme Q inside the mitochondria.  Increased oxidation of Q 
decreases semiquinone levels, subsequently decreasing superoxide anion production [28].  
Increased reduction of the NADP couple enhances regeneration of reduced glutathione, an 
important endogenous antioxidant [28].  Thus, ketone body metabolism protects cells from 
oxidative damage by decreasing ROS production and by enhancing endogenous antioxidant 
capabilities.  As previously discussed, cancer cells are unable to effectively metabolize ketone 
bodies; therefore, we do not expect that ketones would confer the same protective effects onto 
the cancer cell.  HBOT increases ROS production within the cell which can lead to membrane 
lipid peroxidation and cell death [39].  Cancer cells with mitochondrial damage and chaotic 
perfusion naturally produce chronically elevated levels of ROS but are susceptible to oxidative 
damage-induced cell death with even modest increases in ROS [4, 40].  We propose a potential 
mechanism of KD+HBOT efficacy: the KD weakens cancer cells by glucose restriction and the 
inherent anti-cancer effects of ketone bodies while simultaneously conferring a protective 
advantage to the healthy tissue capable of ketone metabolism.  This metabolic targeting 
sensitizes the cancer cells to HBOT-induced ROS production and oxidative damage, contributing 
to the efficacy of combining KD with HBOT.  Additionally, ketone metabolism by the healthy 
tissues likely confers protection against the potential negative consequences of HBOT (CNS 
oxygen toxicity) [41-43].   Recent in vivo studies support the neuroprotective effects of ketone 
esters [44, 45].  These hypothetical mechanisms may contribute to the safety and efficacy of the 
KD+HBOT combined therapy. 
Stuhr and Moen recently published a comprehensive review of the literature on the use of 
HBOT for cancer [46].  The authors concluded that HBOT should be considered a safe treatment 
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for patients with varying malignancies and that there is no convincing evidence its use promotes 
cancer progression or recurrence.  In the literature, there are a substantial number of studies 
indicating that HBOT can induce marked anti-cancer effects in vitro and in animal and human 
studies alike [4, 46, 47].  Evidence is mixed, however, as other studies reported no effect with 
HBOT [4, 46].  Indeed, in our present study, HBOT alone did not improve the outcome of VM 
mice with metastatic cancer, but combining HBOT with KD elicited a dramatic therapeutic 
effect.  Perhaps adding the KD or another metabolic therapy (e.g. 2-deoxyglucose, 3-
bromopyruvate) to HBOT would produce similar results in these previously reported studies 
demonstrating no efficacy due to HBOT alone.  It is important to look for synergistic interactions 
between therapies which may increase the efficacy of cancer treatment.  Scheck and coworkers 
reported complete remission without recurrence in 9 of 11 mice with glioma by combining the 
KD with radiation [48].  Marsh, et al. reported synergy between the restricted ketogenic diet and 
the glycolysis inhibitor 2-deoxyglucose [49].  Might adding HBOT to these combination 
therapies elicit even better results?  Similarly, might the use of adjuvant therapies like KD and 
HBOT enhance patient response to standard care?       
Our study strongly suggests that combining a KD with HBOT may be an effective non-
toxic therapy for the treatment of metastatic cancer.  The efficacy of combining these non-toxic 
treatments should be further studied to determine their potential for clinical use.  Based on the 
reported evidence, it is highly likely that these therapies would not only contribute to cancer 
treatment on their own, but might also enhance the efficacy of current standard of care and 
improve the outcome of patients with metastatic disease. 
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CHAPTER 4: KETONE SUPPLEMENTATION INHIBITS VM-M3 CANCER                
IN VITRO AND IN VIVO 
 
4.1 Chapter Synopsis 
Here we describe the effects of ketone supplementation on VM-M3 cancer in vitro and in 
vivo.  When administered with both standard and ketogenic diets, ketone supplementation 
decreased tumor growth and metastatic spread and extended mean survival time in VM-M3 
mice.  βHB supplementation inhibited VM-M3 cell proliferation and viability in vitro, but had no 
effect on ROS production.  It also inhibited expression of HIF-1α and pAkt, mechanisms which 
are known to elicit anti-cancer effects in vivo.  We also investigated the effects of chronic ketone 
administration on healthy rats, and found that it lowered blood glucose, elevated blood ketones, 
did not affect blood triglycerides or cholesterol, but did alter the concentration of numerous 
blood metabolites which have implications for its anti-cancer effects.     
Portions of this chapter have been previously published in “Poff A, Ari C, Arnold P, 
Seyfried T, D’Agostino D. (2014) Ketone Supplementation Decreases Tumor Cell Viability and 
Prolongs Survival of Mice with Metastatic Cancer. Int. J. of Cancer.” and a copy of this article 
may be found in Appendix C.  See Appendix B for copyright permissions.  Materials and 
methods for the studies presented in this chapter can be found in Appendix A.    
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4.2 Ketone Supplementation Inhibits VM-M3 Cancer in Vitro and in Vivo Independently of 
Glucose Concentration 
While the literature strongly suggests that ketone bodies impede cancer growth in vitro, 
the in vivo efficacy of dietary ketone supplementation has not been adequately examined.  It is 
possible to raise blood ketone levels without the need for carbohydrate restriction by 
administering a source of supplemental ketones or ketone precursors.  1,3-butanediol (BD) is a 
commercially available food additive and hypoglycemic agent that is converted to βHB by the 
liver [32, 33].  The ketone ester (KE) elevates both AcAc and βHB in a dose-dependent manner 
to levels beyond what can be achieved with the KD or therapeutic fasting [34].  Oral 
administrations of BD and KE have been shown to elevate blood ketones for at least 240 min in 
rats [34].  Since ketone bodies appear to elicit anti-cancer effects, and metastasis is the most 
significant obstacle in the successful treatment of neoplasms, we tested the efficacy of ketone 
supplementation the VM-M3 cell line and mouse model of metastatic cancer.    
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Figure 4.1.  βHB decreases VM-M3 cell proliferation and viability in vitro.  (A) VM-M3 
proliferation was inhibited when grown in low (3mM) glucose and/or ketone supplemented 
(5mM βHB) media (Glu: glucose; βHB: β-hydroxybutyrate).  Cell density was significantly less 
in low (3mM) glucose conditions and in both low (3mM) and high (25mM) glucose conditions 
with ketone supplementation (5mM βHB ) at 24, 48, 72, 96, 120, and 144 hours compared to 
high glucose controls (p<0.05; One-Way ANOVA).  Although low (3mM) glucose with ketone 
supplementation (5mM βHB) demonstrated a trend of decreased proliferation compared to low 
(3mM) glucose alone, the difference was not statistically significant.  (B) VM-M3 viability was 
decreased when grown in low (3mM) glucose conditions and in both low (3mM) and high 
(25mM) glucose conditions with ketone supplementation (5mM βHB).  There was a significantly 
smaller percentage of live cells in all treated versus control (high glucose, 25mM) media 
(*p<0.05, ***p<0.001; Unpaired t-test).  (C-F) Live/dead fluorescence of VM-M3 cells grown 
in high (25mM) glucose with and without 5mM βHB.  Results were considered significant when 
p<0.05.  Error bars represent ±SEM. 
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Figure 4.2. βHB inhibits HIF-1α and pAkt expression in VM-M3 cells.  Expression of cancer 
and metabolic signaling molecules in VM-M3 cells grown for 7 days in control media with or 
without 5mM βHB was investigated by western blot analysis.  βHB-treated cells expressed 
significantly less HIF-1α and pAkt than cells grown in control media without βHB (*p<0.05, 
***p<0.001; unpaired t-test).  There was no effect of treatment on p44 MAPK/Erk1, p42 
MAPK/Erk 2, or phospho-mTOR (data not shown).  Error bars represent ±SEM.  Results were 
considered significant when p<0.05.  
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Figure 4.3. Effect of supplemental ketones on tumor bioluminescence.  Ketone supplement 
fed mice demonstrated a trend of slower tumor growth and metastatic spread compared to 
controls.  (A) Representative animals from each group at 21 days post tumor cell inoculation 
showing whole body tumor bioluminescence.  Treated mice exhibited reduced tumor burden and 
metastatic spread.  (B) Whole animal bioluminescence tracked over time as a measure of tumor 
growth rate.  The number of animals alive at each week is presented as the color-coded number 
above the average bioluminescence data points.  (C-E) Bioluminescence of key metastatic 
regions: brain, lungs, and liver.  Treated animals exhibited a trend of slower tumor growth rate 
and decreased metastatic spread compared to controls, although bioluminescence was not 
significantly different from controls.  Error bars represent ±SEM. 
 
Figure 4.4. Supplemental ketones extend survival time in mice with systemic metastatic 
cancer.  (A) Kaplan-Meier survival curve of treatment groups.  BD and KE, but not CR, treated 
mice demonstrated prolonged survival compared to controls (Logrank test for survival 
distribution; p=0.01, p=0.001, and p=0.30 respectively).  (B) Cohort size, mean survival, and 
percent change from mean survival of controls shown.  BD mice exhibited a 51% increase in 
mean survival time compared to controls, while KE mice exhibited a 69% increase in mean 
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survival time compared to controls (*p<0.05; ***p<0.001; One-Way ANOVA).  Results were 
considered significant when p<0.05. 
 
Figure 4.5. Effect of ketone supplementation on blood glucose, blood βHB, urine AcAc, and 
body weight in mice.  (A-C) Glucose and ketones of healthy VM/Dk mice 0-12 hours after 
feeding following 8 hour fast.  BD and KE treated mice demonstrated decreased blood glucose 
and elevated blood βHB following feeding (*p<0.01; **p<0.05; ***p<0.001; Two-Way 
ANOVA).  KE, but not BD, treated mice demonstrated elevated urine AcAc 12 hours after 
feeding (***p<0.001; One-Way ANOVA).  (D-F) Blood glucose, ketones, and body weight of 
survival study VM-M3 mice prior to significant disease onset.  (D) CR and KE treated mice had 
lower glucose than controls by day 7 (**p<0.01; ***p<0.001; One-Way ANOVA).  (E) CR and 
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KE mice had elevated blood βHB compared to controls at day 7 (*p<0.05; ***p<0.001; One-
Way ANOVA).  (F) CR and KE mice had a 20% reduction in body weight  compared to controls 
at day 14 which was sustained for the duration of study (***p<0.001; One-Way ANOVA).  
Results were considered significant when p<0.05.  Error bars represent ±SEM.  (G,H) Blood 
glucose and ketones of VM-M3 cancer mice over the course of the survival study. 
 
Figure 4.6. Decreased blood glucose and weight loss correlated with longer survival.  Linear 
regression analysis of day 7 blood glucose and percent body weight change for all study animals 
revealed a significant correlation to survival time (p=0.0065 and p=0.0046, respectively).  
Results were considered significant when p<0.05.  
 
Ketone supplementation inhibits VM-M3 cancer in vitro and in vivo independent of glucose 
concentration  
The Warburg Effect is the most ubiquitous cancer phenotype, exhibited by most if not all 
cancer types [1].  Exploiting the metabolic deficiencies of cancer cells should be prioritized, 
since this therapeutic strategy would likely prove effective against most cancers.  Mitochondrial 
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dysfunction underlies many aspects of cancer metabolic deficiency and prevents cancer cells 
from effectively utilizing ketone bodies for energy [2, 3].  In the current study, ketone 
supplementation decreased VM-M3 cell proliferation and viability (Figure 4.1), confirming 
similar results demonstrated in other cancer types in vitro [2, 4, 5].  As described in Chapter 1, 
HIF-1 is a transcription factor that mediates the cellular response to oxygen deprivation.  It is 
known to be overly active in cancers and plays a major role in all of the hallmarks of cancer 
including tumorigenesis, proliferation, survival, invasion, and metastasis, and its expression is 
correlated with poor clinical prognosis [6-8].  Many chemotherapies work in part by inhibiting 
HIF-1 signaling [9].   Akt is a serine/threonine kinase that mediates numerous signaling cascades 
including Ras, PI3K, mTOR, insulin receptor, as well as other growth factor and cytokine 
pathways.  The kinase activity of Akt is activated by a phosphorylation event on a carboxy 
terminal serine residue (Ser473).  Akt signaling is enhanced in most cancers by multiple 
mechanisms [10].  In general, its activation elicits a mitogenic effect, enhancing protein 
synthesis, cell cycle progression, proliferation, and survival.  It also enhances the Warburg effect 
by increasing glucose transport and the activity of the glycolytic enzymes.  βHB inhibited both 
HIF-1α and pAkt expression in VM-M3 cells (Figure 4.2).  We therefore hypothesized that 
dietary administration of ketone body precursors would inhibit disease progression in vivo.  
Indeed, dietary administration of ketone precursors, BD and KE, increased mean survival time 
by 51% and 69%, respectively, in VM-M3 mice with metastatic cancer (Figure 4.4).  These data 
support the use of supplemental ketone administration as a feasible and efficacious cancer 
therapy which should be further investigated in additional animal models in order to determine 
potential for clinical use.   
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Ketone supplementation decreased blood glucose following acute administration, 
decreased body weight with chronic administration, and sustained ketosis in vivo, even when 
administered with a high carbohydrate rodent chow in both healthy (VM/Dk) and cancer (VM-
M3) mice (Figure 4.5).  This study demonstrates the ability of dietary administration of BD and 
KE to significantly elevate ketone bodies in vivo for at least 12 hours in healthy VM/Dk mice 
and 7 days in VM-M3 cancer mice (Figure 4.5).  VM-M3 cancer is very aggressive, and health 
of control animals declines rapidly after tumor cell inoculation. With onset of disease 
progression, animal feeding behavior, body weight, and blood metabolites vary considerably.  
Blood and body weight data prior to the onset of significant disease progression in all treatment 
groups (Figure 4.5 D-F) demonstrate the effects of the dietary therapies on blood metabolites in 
VM-M3 cancer mice largely aside from the confounding effects of disease progression.  Figure 
4.5 G and H show blood glucose and βHB levels of VM-M3 mice over the course of the survival 
study.  Disease progression altered feeding behavior, and animals often exhibited low blood 
glucose and elevated blood ketones prior to euthanasia.  For example, nearly all CR mice were 
euthanized in the 5th week of the study, with their declining health reflected by the marked 
increase in blood ketones at week 4 (Figure 4.5 H).    
It is important to note that the metabolic changes associated with acute and chronic 
ketosis are vast and can dramatically affect blood metabolite concentrations.  In previous studies, 
chronic BD and βHB administration have been shown to decrease food intake in the rat and 
pigmy goat [8, 9].  Similarly, Veech and colleagues demonstrated that feeding a ketone ester 
supplemented diet increased malonyl-CoA, an anorexigenic metabolite known to decrease food 
intake [11].  Ketone-induced appetite suppression may account for the decreased blood glucose 
and body weight seen in treated VM-M3 cancer mice (Figure 4.5 F).  Additionally, prior studies 
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suggest that ketones increase insulin sensitivity [11, 12], which may be contributing to the 
decreased circulating blood glucose in KE fed mice.  Blood metabolite levels are dynamic and 
change rapidly with food consumption and tissue utilization.  Because the VM-M3 cancer mice 
were fed ad libitum, blood glucose and ketone levels observed at the time of measurement during 
chronic supplementation were likely affected by variable feeding behavior prior to blood 
measurement.  As mentioned, health status of the animals also altered feeding behavior.  Mice 
reduced food intake and likely experienced cancer-associated cachexia with disease progression, 
conditions which elevate blood ketones endogenously through beta-oxidation of stored fats.  
Furthermore, chronic ketosis enhances ketone utilization by tissues, known as keto-adaptation, 
resulting in lower blood ketone concentrations [13].  All of these factors likely contributed to the 
observed variability in blood glucose and βHB between acute versus chronic administration of 
diet and healthy VM/Dk versus VM-M3 cancer mice (Figure 4.5).    
Previously, dietary intervention in cancer has largely focused on carbohydrate or calorie 
restriction to exploit the Warburg Effect.  CR has been shown to slow disease progression in a 
variety of cancer models [14-18].  As described, dietary induced ketosis often leads to reduced 
appetite, decreased calorie consumption, and decreased body weight, creating the possibility that 
the effects of ketone supplementation could be indirectly due to CR [3].  Interestingly, although 
CR decreased blood glucose and elevated blood ketones, CR mice exhibited a trend of increased 
latency to disease progression and increased survival that was not statistically significant from 
controls in this study (Figures 4.4, 4.5).  As described, some data suggest that elevated ketones 
are responsible for much of the anti-cancer efficacy of the ketogenic diet [19].  Perhaps elevating 
ketones with exogenous sources such as ketone supplementation or a ketogenic diet, rather than 
elevating ketones endogenously through lipolysis such as occurs with CR, provides a more 
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effective anti-cancer strategy.  Additionally, ketone supplementation may preserve lean muscle 
mass to a greater degree than CR, and may therefore support overall health of the organism in 
this way.  Since CR mice demonstrated a trend of increased latency to disease progression and 
survival time, and body weight change was correlated to survival (Figure 4.6), indirect CR likely 
contributed to the efficacy of ketone supplementation but does not account for the significant 
increase in survival time in ketone-fed mice.  Additionally, while BD increased mean survival 
time by 51%, blood glucose was not significantly lower than in control animals, suggesting that 
decreased glucose availability was not the primary mechanism of efficacy (Figures 4.4, 4.5).  KE 
treatment increased mean survival to a greater extent than BD (69% increase from control; 
Figure 4.4).  Notably, blood glucose and body weight was more decreased and ketones were 
more elevated in KE treated animals, possibly due to indirect CR, and perhaps accounts for the 
enhanced efficacy of KE compared to BD treatment (Figure 4.5).  In vitro, 5 mM βHB 
supplementation decreased proliferation rate and viability of VM-M3 cells, even when added to 
25 mM glucose media (Figure 4.1).  Indeed, ketone supplementation was as effective as glucose-
restriction (low, 3mM glu) treatment in decreasing VM-M3 cell proliferation and viability 
(Figure 4.1).  These data support the in vitro and in vivo conclusions of Fine and others 
suggesting that ketone bodies can inhibit cancer progression independently of other factors such 
as carbohydrate or calorie restriction [2, 4, 5, 19]. 
Listanti and colleagues have published reports that tumor-associated fibroblasts produce 
ketone bodies to fuel nearby cancer cells [20, 21].  In these reports, the authors co-culture 
immortalized fibroblasts genetically altered to overexpress rate-limiting ketone production 
enzymes with breast cancer cells genetically altered to overexpress ketone utilization enzymes.  
While this phenomenon may occur in the system created by the authors, there is no evidence that 
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this situation would occur naturally in vivo.  As described, the literature as a whole strongly 
suggests that cancer cells of various tissue types are unable to effectively use ketone bodies for 
fuel.  Many cancers do not express the succinyl CoA 3-ketoacid CoA transferase (SCOT) 
enzyme which is necessary for ketone body utilization [22], while several reports have 
demonstrated a notable deficiency of cancer cell ketone metabolism in vitro [2, 23].  It is also 
widely accepted that ketone production occurs nearly exclusively in the liver, and there is no 
known metabolic pathway by which fibroblasts could produce ketones from glucose.  Without 
evidence to support this phenomenon in a natural cellular environment, we continue to accept the 
notion that most cancer cells cannot effectively metabolize ketones for energy.     
The ketogenic diet has been shown to enhance the efficacy of both radiation and 
chemotherapy in vivo [24-26].  As supplemental ketones mimic the physiological ketosis induced 
by the ketogenic diet, combining supplemental ketone therapy with standard of care could 
produce similar effects, even if administered with a standard diet.  Furthermore, the 
neuroprotective effects of ketone metabolism have been widely documented [27].  Ketone 
metabolism protects normal cells from oxidative damage by decreasing mitochondrial ROS 
production and enhancing endogenous antioxidant defenses [28].  Radiation and chemotherapy 
work in large part by inducing ROS production in the tumor, but simultaneously incur damage to 
normal tissue.  Ketone metabolism by healthy tissue would likely mitigate some of the adverse 
side effects of standard of care as ketones have been shown to protect against oxidative stress 
[28, 29].  Our data strongly suggest that supplemental ketone administration could provide a 
safe, feasible, and cost-effective adjuvant to standard care that should be further investigated in 
pre-clinical and clinical settings. 
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4.3 Effect of Ketone-Supplemented Ketogenic Diets on VM-M3 Cancer 
 
 
Figure 4.7.  Blood glucose, βHB, and body weight of KD+BD and KD+KE treated VM-M3 
mice prior to significant disease onset.  VM-M3 mice with metastatic cancer were fed either 
standard rodent chow (control), BD-supplemented ketogenic diet (KD+BD), or KE-
supplemented ketogenic diet (KD+KE).  (A, C) KD+BD and KD+KE treated mice had 
significantly decreased blood glucose and body weight compared to control mice by day 7 
(**p<0.01, ***p<0.001; one-way ANOVA).  (B) KD+BD and KD+KE treated mice had 
significantly increased blood βHB compared to control mice by day 7 (*p<0.05, ***p<0.001; 
one-way ANOVA).  Error bars represent ±SEM.  Results were considered significant when 
p<0.05. 
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Figure 4.8.  Effect of KD+BD and KD+KE treatment on tumor growth in VM-M3 mice. 
VM-M3 mice with metastatic cancer were fed either standard rodent chow (control), BD-
supplemented ketogenic diet (KD+BD), or KE-supplemented ketogenic diet (KD+KE).  (A) 
Treated mice exhibited a trend of reduced bioluminescence suggesting lessened tumor burden 
and metastatic spread compared to controls.  (B) Whole animal bioluminescent signal was 
recorded over time as a measure of tumor growth rate.  Treated mice exhibited a trend of slower 
tumor growth; however, bioluminescent signal was not significantly different compared to 
controls (p>0.05; one-way ANOVA).   
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Figure 4.9. Effect of KD+BD and KD+KE treatment on metastatic spread in VM-M3 mice 
by in vivo bioluminescent imaging.  In vivo bioluminescent imaging of key metastatic regions 
in VM-M3 mice 21 days post inoculation was performed as an indicator of metastatic tumor size 
and spread.  KD+BD-treated mice exhibited a trend of reduced spread to the brain, and KD+KE-
treated mice exhibited a trend of reduced spread to the brain and lungs, but these difference were 
not significant from controls (p>0.05; One-way ANOVA).  Error bars represent ±SEM.  
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Figure 4.10. Effect of KD+KE treatment on metastatic spread in VM-M3 mice by ex vivo 
bioluminescent imaging.    Ex vivo bioluminescent imaging of organs harvested from control 
and KD+KE treated mice 21 days post inoculation was performed as a more sensitive method of 
measuring metastatic tumor size and spread.  KD+KE-treated mice exhibited a trend of reduced 
spread to the brain, lungs, kidneys, spleen, adipose, and liver, but this difference was only 
significant from controls for the adipose tissue (p<0.05; unpaired t-test).  Error bars represent 
±SEM.  
 
Figure 4.11. Effect of KD+KE treatment on metastatic liver tumor size and vascularization.  
Morphology and vascularization of KD+KE-treated mouse liver tumors 21 days after VM-M3 
cell inoculation were analyzed by H&E staining and CD31 immunohistochemistry.  In general, 
tumors from KD+KE-treated mice were smaller with more well-defined borders (A, C) and 
exhibited a trend of reduced vascularization (B, D, E) that was not significantly different from 
controls (p>0.05; unpaired t-test).  Error bars represent ±SEM.   
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Figure 4.12.  Ketone supplemented ketogenic diets extend survival time in VM-M3 mice 
with metastatic cancer.  VM-M3 mice with metastatic cancer were fed either standard rodent 
chow (control), BD-supplemented ketogenic diet (KD+BD), or KE-supplemented ketogenic diet 
(KD+KE).  (A) Kaplan-Meier survival curve of study groups.  KD+BD and KD+KE treated 
mice demonstrated significantly prolonged survival compared to controls (p<0.05; log-rank 
Mantel-Cox test for survival distribution).  (B) Cohort size (N), mean survival time, and percent 
increase in mean survival time from controls shown.  KD+BD and KD+KE treated mice 
exhibited a 61.2% and 65.4% increase in mean survival time compared to controls, respectively 
(**p<0.01; one-way ANOVA).  Results were considered significant when p<0.05.   
 
Ketone-Supplemented Ketogenic Diets Prolong Survival in VM-M3 Mice with Metastatic Cancer 
Please note that the KD+KE survival study data is also included in the manuscript under 
revision in Chapter 5.  It has been included here along with the unpublished BD-supplemented 
KD data for clarity purposes.  Blood glucose and body weight were significantly decreased, and 
blood βHB significantly increased, in mice receiving ketone supplements prior to significant 
disease onset (Figure 4.7).  These effects were more pronounced in KD+KE treated mice whose 
body weight loss suggests some degree of calorie restriction (CR).  Our study one ketone 
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supplementation and body weight matched calorie restricted VM-M3 mice demonstrated that the 
anti-cancer effects of ketone supplementation may be enhanced by, but is not due to CR alone 
[30].  Bioluminescent imaging of mice demonstrated a trend of decreased tumor growth rate, but 
overall tumor burden was not significantly less than controls in either treatment group at 3 weeks 
(Figure 4.8).  A similar result was observed with in vivo bioluminescence of metastatic regions.  
At 3 weeks, KD+BD treatment elicited a trend of reduced spread to the brain, and KD+KE 
treatment elicited a trend of reduced spread to the brain and lungs by in vivo bioluminescent 
imaging; however, these differences were not significantly different from control mice (Figure 
4.9).  Ex vivo bioluminescent imaging of organs harvested from KD+KE treated mice 21 days 
post VM-M3 inoculation showed similar results: there was a trend of decreased metastasis to the 
brain, lungs, liver, spleen, and kidneys, and a significant decrease in metastatic tumor burden in 
the adipose sample compared to controls (Figure 4.10).  
Morphological and immunohistochemical analysis of liver tissue demonstrated that 
KD+KE treated mice had smaller metastatic tumors with more well-defined borders and a trend 
of decreased vascularity compared to those from control animals, although this difference was 
not statistically significant (Figure 4.11).  The trend of decreased vascularization may be due to 
an inhibition of angiogenesis, perhaps subsequent to inhibition of HIF-1, a potent stimulator of 
VEGF expression.  Alternatively, inhibition of tumor growth may have precluded the need for 
angiogenesis at the observed time point in treated mice.  Considering that ketone 
supplementation inhibits VM-M3 cell proliferation and viability and inhibits HIF-1 signaling in 
vitro, it is likely that both of these phenomenon contribute to any potential decreased 
vascularization in the KD+KE treated mouse liver metastases.   
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We had hypothesized that we could enhance the anti-cancer efficacy of the KD with 
ketone supplementation.  We found this to be true.  While KD-USF, the specific KD used for this 
study, prolonged mean survival time of VM-M3 mice by approximately 45% (Chapter 5, Figure 
5.8), KD+BD and KD+KE treatment prolonged mean survival time by 61.2% and 65.4%, 
respectively (Figure 4.12).  This study strongly suggests that ketone supplemented ketogenic 
diets can inhibit progression of metastatic cancer in vivo. 
 
4.4 Effect of Chronic Oral Administration of Ketone Supplements in Rats 
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Figure 4.13.  Effect of chronic ketone administration on blood glucose in rats.  Rats received 
a daily 5 g/kg dose of water (control), BD, or KE (N≥8) via intragastric gavage for 29 days.  
Blood glucose was significantly reduced in KE-treated, but not BD-treated, rats for 
approximately 1 hour following ketone supplement administration (*p<0.05, **p<0.01, 
***p<0.001; one-way ANOVA).  Error bars represent ±SEM.  Results were considered 
significant when p<0.05.  
 
Figure 4.14.   Effect of chronic ketone administration on blood βHB in rats.  Rats received a 
daily 5 g/kg dose of water (control), BD, or KE (N≥8) via intragastric gavage for 29 days.  Blood 
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βHB was significantly elevated in both BD-treated and KE-treated rats for approximately 4-8 
hours following ketone supplement administration (*p<0.05, **p<0.01, ***p<0.001; one-way 
ANOVA).  Error bars represent ±SEM.  Results were considered significant when p<0.05.  
 
 
Figure 4.15.  Correlation between blood glucose and blood βHB following oral ketone 
supplement administration.  Rats received a daily 5 g/kg dose of water (control), BD, or KE 
(N≥8) via intragastric gavage for 29 days.  Correlation between blood glucose and blood βHB 
concentration following acute (week 0; day 0) and chronic (week 4; day 28) ketone supplement 
administration was determined by linear regression analysis.  There was a significant inverse 
correlation between blood glucose and blood βHB concentration in BD-treated rats at week 4 
(*p<0.01), and a strong trend towards an inverse relationship between blood glucose and blood 
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in BD-treated rats at week 0 and in KE-treated rats at weeks 0 and 4.  Error bars represent 
±SEM.  Results were considered significant when p<0.05.  
 
Figure 4.16.  Effect of chronic ketone administration on blood triglycerides, total 
cholesterol, HDL, and LDL in rats.  Rats received a daily 5 g/kg dose of water (control), BD, 
or KE (N≥8) via intragastric gavage for 29 days.  On day 28, blood triglycerides, total 
cholesterol, and HDL were measured.  LDL cholesterol was determined from the measured 
parameters with the Friedewald equation.  There was no significant effect of chronic 
administration of BD and KE on blood lipid levels (p>0.05; one-way ANOVA).  Error bars 
represent ±SEM.    
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Table 4.1. Global metabolomics profiling of serum from rats following chronic 
administration of KE.  Rats received a daily 5 g/kg dose of water (control) or KE (N≥8) via 
intragastric gavage for 29 days.  Serum was taken from rats on day 29 and global metabolomics 
profiling was performed at Metabolon Inc. using gas and liquid-chromatography with tandem 
mass spectrometry.  155 of 388 known metabolites were significantly changed from control rats 
(*p<0.05, **p<0.01, ***p<0.001; Welch’s two-sample t-test).  Metabolites affected by KE-
treatment with potential relevance to the anti-cancer efficacy of ketone supplementation are 
shown.  Results were considered significant when p<0.05 and are indicated by solid red or green 
backgrounds.  Metabolites that exhibited a trend of change but were not statistically significant 
(0.05<p<0.10) are indicated by a shaded red or green background. 
 
Super Pathway Sub Pathway Biochemical Name Fold of Change from Control
glutathione, oxidized (GSSG) 17.34*
cysteine-glutathione disulfide 2.41**
Glutamate Metabolism pyroglutamine 0.42**
Polyamine Metabolism spermidine 1.98*
DTGTTSEFXEAGGDXR 0.65*
ATTDSDKVDXSXA 0.68
DSDKVDXSXAR 2.07*
carnosine 3.23*
anserine 5.66**
ribose 5-phosphate 4.86*
ribulose/xylulose 5-phosphate 8.18*
citrate 1.99***
alpha-ketoglutarate 1.98**
fumarate 1.92*
malate 2.03**
acetoacetate 8.84***
3-hydroxybutyrate (BHBA) 15.78***
1-pentadecanoylglycerophosphocholine (15:0) 1.36**
2-palmitoylglycerophosphocholine 0.8*
2-palmitoleoylglycerophosphocholine 0.5**
2-stearoylglycerophosphocholine 0.7**
2-oleoylglycerophosphocholine 0.75**
1-linoleoylglycerophosphocholine (18:2n6) 0.79**
2-linoleoylglycerophosphocholine 0.76*
1-nonadecanoylglycerophosphocholine(19:0) 0.64*
1-dihomo-linoleoylglycerophosphocholine (20:2n6) 0.67*
1-eicosenoylglycerophosphocholine (20:1n9) 0.6**
1-eicosatrienoylglycerophosphocholine (20:3) 0.68*
1-arachidonoylglycerophosphocholine (20:4n6) 0.88*
2-arachidonoylglycerophosphocholine 0.77*
1-docosapentaenoylglycerophosphocholine (22:5n3) 0.72**
1-palmitoylplasmenylethanolamine 1.37
1-oleoylplasmenylethanolamine 1.98*
1-linoleoylglycerophosphoethanolamine 0.66*
1-stearoylglycerophosphoserine 2.89*
1-linoleoylglycerophosphoserine 3.45**
alpha-tocopherol 0.55**
beta-tocopherol 0.76**
gamma-tocopherol 0.61*
alpha-CEHC sulfate 0.52**
Hemoglobin and Porphyrin Metabolism bilirubin (Z,Z) 0.4**
Glutathione Metabolism 
Peptide
Dipeptide Derivative
Cofactors and Vitamins
Tocopherol Metabolism 
Lysolipid 
Ketone Bodies
TCA Cycle 
Pentose Phosphate Pathway
Fibrinogen Cleavage Peptide 
Amino Acid
Carbohydrate
Energy 
Lipid
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Chronic oral administration of ketone supplements lowers blood glucose, elevates blood ketones, 
and dramatically alters serum metabolites in rats 
Chronic ketone administration induces ketoadaptation, a physiologic state characterized 
by a shift away from glucose metabolism and towards fat and ketone body metabolism.  There 
are many metabolic changes with sustained ketosis that may underlie its multifaceted therapeutic 
potential, so we studied how blood glucose, blood ketones, blood lipids, and other biochemical 
metabolites are affected by chronic KE administration.  Over a 29 day period, rats receiving a 
daily 5 g/kg dose of KE showed a drop in blood glucose for approximately one hour following 
administration.  In general, this drop in blood glucose became more substantial over the course 
of the study (Figure 4.13), suggesting that chronic ketosis enhances the hypoglycemic effect of 
ketone administration.  Veech and colleagues have demonstrated that administration of a similar 
ketone ester simultaneously decreased blood glucose and blood insulin by approximately 50%, 
suggesting that the hypoglycemic effect of ketones is caused by enhancing insulin sensitivity 
[11].  Our results support this work, showing that ketone ester supplementation elicits a 
hypoglycemic effect in vivo.  Since glucose is the major energy source for cancer, and its 
elevation is directly correlated to tumor growth, KE supplementation as a cancer therapy may 
work in part by inhibiting glucose availability to the tumor.  Aside from the known protein-
sparing effects of ketones, if ketosis enhances insulin sensitivity, it likely increases glucose 
uptake by the insulin-sensitive skeletal muscle.  Together, these effects would help support 
muscle tissue health and function, suggesting another possible benefit of KE supplementation in 
slowing muscle wasting associated with cancer cachexia. 
 Blood βHB levels were elevated for approximately 4 hours following KE administration 
and 8 hours following BD administration (Figure 4.14), demonstrating the ability of oral ketone 
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supplementation to induce sustained ketosis in vivo.  It is important to remember, however, that 
while BD is metabolized to βHB, KE metabolism produces both βHB and AcAc.  The 
commercially available blood ketone meters used in this study offer the most cost feasible 
method of measuring blood ketone levels, but are only able to measure βHB, not AcAc.  
However, metabolomics analysis indicated a nearly 9-fold increase in AcAc from KE-treated rats 
compared to controls (Table 4.1).  Thus, total blood ketones was likely higher in KE-treated than 
BD-treated animals.  In general, blood βHB levels decreased more quickly during weeks 1-4 
compared to the first administration (week 0) (Figure 4.14).  This difference is possibly due to an 
increase in tissue utilization following ketoadaptation that comes with chronic ketosis; however, 
it is also possible that excess ketones were excreted in the urine, but this was not measured.  
Notably, the increase in blood βHB was correlated to the decrease in blood glucose following 
ketone supplementation (Figure 4.15), further supporting the hypothesis that ketones enhance 
insulin sensitivity.    
 The rats used in this study had not reached their full adult body size yet, and therefore 
over the four week study, control animals exhibited changes in their blood lipid profile from 
baseline associated with normal aging (Figure 4.16).  Rats receiving BD and KE demonstrated 
similar changes in triglycerides, total cholesterol, HDL, and LDL from baseline as control rats, 
indicating that there was no significant effect of chronic ketone supplementation on blood lipids 
(Figure 4.16).  Although the evidence is controversial and highly dependent on the specific 
macro and micronutrient composition of the diet, a common concern regarding the KD is its 
potential negative effect on blood triglyceride and cholesterol levels [31, 32].  Thus, ketone 
supplementation could provide an alternative method to induce ketosis, or a way to enhance the 
effects of the KD, without a major influence on the blood lipid profile.   
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Global metabolomics profiling of serum from chronic KE-treated rats revealed 155 
metabolites which were significantly altered compared to control.  A selection of affected 
metabolites with potential relevance to the anti-cancer effects of ketone supplementation is 
provided in Table 4.1.  These metabolite changes provide preliminary insight into several 
potential mechanisms of the anti-cancer efficacy of KE supplementation for future studies.  
Unexpectedly, markers of both oxidative stress (oxidized glutathione, GSSG) and antioxidant 
capacity (carnosine and anserine) were elevated, suggesting a heightened state of oxidative stress 
and antioxidant defense with KE supplementation.  Generally, ketone metabolism is known to 
decrease ROS production and enhance endogenous antioxidant capacity [33].  It should be noted, 
however, that the dose of KE-administration was relatively high, and delivered as a daily bolus.  
It is likely that delivering a lower dose over a more sustained period of time, such as when mixed 
into food, would affect this response.  As described, ROS production, antioxidant capacity, and 
redox state dramatically influences cancer progression [34].  Both pro-oxidant and anti-oxidant 
therapies have shown anti-cancer effects in vitro and in vivo [35].  The altered redox state 
induced by KE administration likely plays a role in its anti-cancer effects and provides a clear 
point of interest for future studies into the molecular mechanisms of ketone metabolism in 
cancer.         
The antioxidant carnosine was nearly 4-fold higher in KE-treated rats compared to 
controls (Table 4.1).   Carnosine has been investigated as a potential anti-neoplastic therapeutic 
[36], and has been shown to inhibit cancer cell viability in vitro, and inhibit tumor growth and 
metastatic spread and increase survival in vivo [36-39].  Carnosine is a known antioxidant, but 
the extent of its physiological functions remain unknown [40, 41].  One study determined that 
carnosine inhibits anaerobic glycolysis, which suggests that it may target the Warburg effect in 
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cancer [42].  Alteration of redox capacity by carnosine may play a role in its anti-cancer effects 
as well.  KE-induced elevation of carnosine provides an interesting potential mechanism for use 
of KE supplementation as a cancer therapy.   
Lysophospholipids (LP) are extracellular lipid mediators that bind to a family of G 
protein coupled receptors (GPCRs) and affect numerous cellular functions including 
differentiation, proliferation, survival, adhesion, and invasion [43].  LPs elicit many growth 
factor-like effects, and not surprisingly, LP signaling is altered in cancer [44, 45].  Studies have 
found elevated LP variants in the blood and peritoneal fluid of ovarian cancer patients, while LP 
receptor elevation and signaling helps mediate survival in ovarian cancer cell lines [45].  LP 
receptor overexpression induces tumorigenesis and metastasis in mice, and knockdown elicits 
opposite effects [46].  Several lysophospholipids were significantly decreased in KE-treated rats 
(Table 4.1), offering insight into numerous potential mechanisms by which ketones affect cancer 
cell growth and survival.       
In our VM-M3 mouse studies, KE was mixed into the food and fed ad libitum, allowing 
continual delivery of the KE in smaller doses as the mice fed throughout the day.  Compared to a 
bolus administration, multiple daily doses or inclusion in food would likely provide more 
sustained beneficial effects.  The metabolomics profiling data presented here help us to 
understand the metabolic consequences of KE administration and offers insight into potential 
mechanisms of action by which ketone supplementation may inhibit cancer progression for 
future studies.   
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CHAPTER 5: COMBINATION METABOLIC THERAPY ELICITS POTENT ANTI-
CANCER EFFECTS IN VM-M3 CANCER IN VITRO AND IN VIVO 
 
5.1 Chapter Synopsis 
Here we describe the effects of combination ketogenic diet, ketone supplementation, and 
hyperbaric oxygen therapy on VM-M3 cancer in vitro and in vivo.  In the previous chapters, we 
demonstrated that these therapies were effective to varying degrees as stand-alone treatments; 
however, combining them elicited potent, synergistic anti-cancer effects in the VM-M3 model 
that provided the most significant response of the multiple therapeutic regimens tested in this 
study.  Proliferation and viability was decreased and ROS production increased in VM-M3 cells 
receiving combination low glucose, βHB, and HBOT.  VM-M3 mice receiving combination 
KD+KE+HBOT therapy had a significant reduction in tumor growth rate and metastatic spread, 
metastatic tumor vascularization, and lived twice as long as control animals.  We hypothesize 
that this novel combination therapy could provide an effective stand-alone or adjuvant treatment 
option for aggressive cancers of multiple cancer types.   
 
Portions of this chapter have been taken from a manuscript accepted with revisions in 
PLOS One:  Poff A, Ward N, Seyfried T, Arnold P, D’Agostino D. (2014) Non-toxic metabolic 
management of metastatic cancer in VM mice: Novel combination of ketogenic diet, ketone 
supplementation, and hyperbaric oxygen therapy.  A copy of this article may be found in 
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Appendix C.  See Appendix B for copyright permissions.  Materials and methods for the studies 
presented in this chapter can be found in Appendix A.    
 
5.2 Combination Metabolic Therapy Inhibits VM-M3 Cancer in Vitro and in Vivo 
As described in chapter 2, the KD, ketone supplementation, and HBOT are three 
metabolic therapies which target overlapping metabolic pathways that are critical to cancer 
progression and are especially prominent in metastatic cells.  In chapter 3, we demonstrated that 
ketosis and HBOT created a physiological environment that was not supportive of metastatic 
cancer growth and survival in the VM-M3 model of metastatic cancer.  In chapter 4, we 
demonstrated that supplemental ketone administration could induce a state of therapeutic ketosis, 
inhibit tumor growth and prolong survival as a stand-alone therapy, and improve the anti-cancer 
response of the KD in this model.  In hopes of further understanding the potential use of these 
metabolic therapies, and in an attempt to pursue the maximal therapeutic response of the novel 
combination of ketosis and hyperbaric oxygen, we investigated the effects of combining the KD, 
KE, and HBOT in VM-M3 mice in vivo and mimicking this physiological environment VM-M3 
cells in vitro.   
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Figure 5.1.  Combination metabolic therapy decreases VM-M3 cell proliferation in vitro.  
VM-M3 cells were grown in conditions mimicking metabolic therapy, including combinations of 
high to low glucose media, ketone supplementation, and daily HBOT sessions.  Cell density was 
measured with trypan blue hemocytometry to produce a growth curve over 96 hours.  (A) 
Proliferation was inhibited when treated with decreasing glucose concentration and adjuvant 
HBOT.  (B) Combining low glucose, ketone supplementation, and HBOT resulted in a marked 
decrease in cell proliferation which was significant from control at all time points tested.  
(p<0.05; one-way ANOVA).  Cells receiving combination therapy had a significant decrease in 
proliferation compared to cells treated with LG only at 24, 48, and 72 hours (p<0.05; one-way 
ANOVA), and exhibited a non-significant trend of decreased proliferation compared to LG + 
HBOT treated cells for the duration of the growth curve.  Results were considered significant 
when p<0.05.  Error bars represent ±SEM. 
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Figure 5.2.  Combination metabolic therapy decreases VM-M3 cell viability in vitro.  VM-
M3 cells were treated with high (control; 25mM) or low (LG; 3mM) glucose 24 hours, with or 
without one session of hyperbaric oxygen.  Viability was measured with calcein AM and Ethd-1 
fluorescence microscopy.  (A-B) LG and LG+βHB+HBOT treatment decreased viability 
compared to control (***p<0.001; one-way ANOVA).  Results were considered significant when 
p<0.05.  Error bars represent ±SEM. 
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Figure 5.3.  Metabolic therapy increases ROS production and decreases HIF-1α expression 
in VM-M3 cells.  (A-B)  VM-M3 cells were treated for 24 hours with individual or combination 
metabolic therapies: LG, βHB, HBOT, or LG+βHB+HBOT.  Superoxide production was 
measured with DHE fluorescence microscopy and was significantly increased with HBOT 
(***p<0.001; one-way ANOVA).  (C-D)  VM-M3 cells were treated for 7 days in control media 
with either ketone supplementation (βHB) or daily hyperbaric oxygen sessions (HBOT).  HIF-1α 
expression was measured by western blot analysis and was significantly decreased with βHB and 
HBOT treatment (***p<0.001; one-way ANOVA).  Results were considered significant when 
p<0.05.  Error bars represent ±SEM. 
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Figure 5.4. Blood glucose, βHB, and body weight of VM-M3 survival study mice prior to 
significant disease onset.  (A-C) KD+KE treated mice had significantly decreased blood 
glucose and body weight and increased blood βHB compared to control mice by day 7 
(**p<0.01, ***p<0.001; one-way ANOVA).  KD+KE and KD+KE+HBOT mice exhibited 
increased blood βHB compared to controls by day 7 (***p<0.001; one-way ANOVA).  KD+KE 
mice had a significant reduction in body weight by day 7 (***p<0.001; one-way ANOVA).  
Results were considered significant when p<0.05.  Error bars represent ±SEM.   
 
149 
 
Figure 5.5. Combination metabolic therapy slows tumor growth and inhibits metastatic 
spread.  (A) In vivo bioluminescence imaging of representative animals from each treatment 
group 3 weeks post tumor cell inoculation.  Treated mice exhibited reduced tumor burden and 
metastatic spread.  (B) Whole animal bioluminescence (photons/sec) was tracked over time as a 
measure of tumor growth rate.  In order to avoid misleading representation of tumor burden, data 
for treatment groups where ≥50% of animals had succumbed to disease progression are no longer 
shown.  Tumor bioluminescence was highly variable, but treated animals demonstrated a notable 
trend of slower tumor growth compared to controls throughout the study.  At week 3, 
KD+KE+HBOT mice had significantly less bioluminescence than control animals (**p<0.01; 
one-way ANOVA).  (C-E) Bioluminescence of key metastatic regions 21 days after tumor cell 
inoculation demonstrated a marked reduction in metastatic tumor burden and spread for treated 
animals.  KD+KE+HBOT mice had significantly less metastatic spread to the brain, lung, and 
liver compared to controls at 3 weeks (*p<0.05, **p<0.01; one-way ANOVA).  Error bars 
represent ±SEM.  Results were considered significant when p<0.05. 
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Figure 5.6.  Effect of KD+KE+HBOT treatment on metastatic spread by ex vivo 
bioluminescence.  VM-M3 mice received either standard rodent chow (control) or 
KD+KE+HBOT treatment for 21 days following tumor cell inoculation.  Organs were harvested 
and bioluminescent signal recorded as a measure of metastatic spread.  KD+KE+HBOT treated 
mice exhibited significantly decreased bioluminescence in the brain, kidneys, spleen, lungs, 
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adipose, and liver (***p<0.001; unpaired t-test).  Error bars represent ±SEM.  Results were 
considered significant when p<0.05. 
 
 
Figure 5.7. Effect of KD+KE+HBOT treatment on metastatic liver tumor size and 
vascularization.  Morphology and vascularization of KD+KE+HBOT-treated mouse liver 
tumors were analyzed by H&E staining and CD31 immunohistochemistry.  Tumors from 
KD+KE+HBOT-treated mice were smaller with more well-defined borders (A, C) and exhibited 
a significant reduction in vascularization (B, D, E) from controls (*p<0.05; unpaired t-test).  
Error bars represent ±SEM. 
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Figure 5.8. Combination metabolic therapy extends survival time in mice with metastatic 
cancer.  (A) Kaplan-Meier survival curve of study groups.  KD, KD+KE, and KD+KE+HBOT 
treated mice demonstrated prolonged survival compared to controls (p=0.03, p=0.009, and 
p<0.0001, respectively; log-rank Mantel-Cox test for survival distribution).  (B) Cohort size (N), 
mean survival (days), and percent increase in mean survival time from control.  KD, KD+KE, 
and KD+KE+HBOT treated mice exhibited a 44.6%, 65.4%, and 103.2% increase in mean 
survival time compared to controls, respectively (*p<0.05, **p<0.01, ***p<0.001; one-way 
ANOVA).  Results were considered significant when p<0.05. 
 
Combination metabolic therapy inhibits VM-M3 cancer in vitro and in vivo 
Metastasis remains the largest obstacle in identifying effective therapies for the long-term 
management of or a cure for cancer.  A lack of animal models which reflect the metastatic 
phenotype prevents major improvements in patient care.  The major goal of this study was to 
investigate the anti-cancer efficacy of a novel combination of metabolic therapies – the ketogenic 
diet, ketone supplementation, and hyperbaric oxygen – in a mouse model of aggressive 
metastatic cancer that recapitulates much of the metastatic phenotype seen in invasive human 
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cancers [1-4].  Individually, these therapies inhibited proliferation and viability in vitro, slowed 
disease progression in vivo, and when combined, elicited potent anti-cancer effects by inhibiting 
metastatic spread and doubling the survival time of mice with systemic, metastatic disease.     
We have previously shown that ketone supplementation and combination ketogenic diet 
with HBOT slowed cancer progression in the VM-M3 model of metastatic cancer [5, 6].  We 
hypothesized that combining these therapeutic regimens could provide an even more significant 
response in this model.  The KD has been used clinically to treat pediatric refractory epilepsy for 
nearly a century, and is known to be a safe and feasible option for patients [7, 8].  HBOT is an 
approved therapy for several disease states, including decompression sickness, carbon monoxide 
poisoning, and radionecrosis [9].  Its use and safety is well-characterized and understood [9, 10].  
Exogenous ketone ester supplementation is a novel therapy that is also safe and feasible [11, 12].  
When ketone supplementation is administered properly, blood ketone levels remain in normal 
physiological levels and do not approach the dangerous levels associated with diabetic 
ketoacidosis (up to 20 mM).  Ketone supplementation can be used, however, to elevate blood 
ketone levels to a therapeutic range of 2-7mM [6], which is reported to be beneficial in a vast 
array of disease states, including epilepsy, Alzheimer’s disease, and other neurological disorders 
[7, 13-19].  Importantly, these treatments represent non-toxic alternative or adjuvant therapies, 
which could be readily implemented clinically if their effects hold up in human trials.   
The VM-M3 model exhibits rapid, systemic metastasis following s.c. inoculation [1].  As 
demonstrated by the in vivo bioluminescent imaging (Figure 1), primary tumor growth and 
pattern of metastatic spread can be highly variable, such as is seen in many human metastatic 
cancers.  The KD, ketone supplementation, and HBOT induced a trend of slowed tumor growth 
rate in vivo, which was significant in mice receiving combination therapy (Figure 5.5) [5, 6].  
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The effect of these metabolic therapies on proliferation and viability in vitro mimicked the 
effects seen in vivo.  Both βHB and HBOT significantly decreased VM-M3 cell proliferation, 
and this effect was enhanced by decreasing blood glucose (Figure 5.1) [6].  We showed 
previously that βHB decreased VM-M3 cell viability, even in the presence of high glucose, but 
this effect was enhanced by lowering glucose concentration [6].  HBOT alone did not increase 
survival time in vivo, and although there was a trend of decreased viability in vitro, this was not 
statistically significant; however, combining HBOT with ketosis elicited potent anti-cancer 
effects in mice and cells (Figures 3.1, 5.8) [5].  Taken together, these studies suggest that 
combining therapeutic ketosis with HBOT creates a unique physiologic and metabolic 
environment that is not conducive to rapid cancer cell proliferation and survival.   
Blood glucose and body weight decreased and blood βHB increased in mice receiving 
KD+KE therapy by day 7, prior to the onset of significant disease progression (Figure 5.4).  As 
would be expected, blood glucose was lower and blood βHB was more elevated in KD+KE mice 
compared to KD alone.  KD+KE mice did lose approximately 20% of their initial body weight, 
suggesting a potential therapeutic contribution from calorie restriction.  However, we previously 
showed that the anti-cancer effects of KE supplementation was not due to CR in body weight 
matched animals (Figure 4.4) [6].  Interestingly, at day 7, KD+KE+HBOT treated mice had 
increased blood βHB, but blood glucose and body weight were not significantly different from 
controls.  The discrepancy between these two groups receiving the same dietary therapy is 
unclear.  Alteration of tissue oxygenation is known to affect metabolic capacity and blood 
metabolite levels [20].  Blood glucose decreases immediately following HBOT sessions in both 
animals and humans [21].  This may be due to an increase in insulin secretion and tissue glucose 
utilization which has been reported with HBOT [22-25].  In our study, blood metabolites were 
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measured several hours after HBOT.  Perhaps HBOT-induced glucose utilization by the brain 
and peripheral tissues stimulated gluconeogenesis or feeding behavior in the VM-M3 mice.  This 
could possibly explain why glucose was not decreased at the time of blood measurement and 
why these animals did not lose weight as the KD+KE mice did.  Similarly, HBOT has been 
shown to enhance weight gain in head and neck cancer patients following surgery and radiation 
[26]. 
In order to provide a more in depth understanding of the effect of combination 
KD+KE+HBOT therapy on metastatic spread, ex vivo bioluminescent imaging was performed on 
organs harvested from control and treated animals 21 days post tumor cell implantation (Figure 
5.6).  The results echoed what was observed with in vivo bioluminescent imaging of metastatic 
regions (Figure 5.5).  Control animals exhibited significant metastatic spread to the brain, lungs, 
liver, and adipose tissue, and a small degree of metastatic spread to the kidneys and spleen 
(Figure 5.6).  Metastatic spread to all harvested organs was significantly reduced, or below 
detectable threshold, in KD+KE+HBOT treated animals (Figure 5.6).  Morphological and 
immunohistochemical analysis of livers from KD+KE+HBOT treated mice revealed only 
micrometastatic lesions with little notable vascularization compared to controls (Figure 5.7).  
These data suggest that combination therapy inhibits metastatic spread and metastatic tumor 
vascularization, which likely contributes to its potent ability to prolong survival time in VM-M3 
mice (Figure 5.4).     
As expected, HBOT increased ROS production in VM-M3 cells when administered 
alone, or in combination with LG+βHB (Figure 5.3).  Although cancer cells thrive in a state of 
elevated basal ROS production, they are very sensitive to modest increases or decreases in ROS 
or alterations in redox or antioxidant state [27, 28].  Furthermore, the differential susceptibility of 
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cancer and normal cells to glucose deprivation has been shown to be mediated by superoxide and 
hydrogen peroxide production and signaling [29, 30].  This may help explain why combining 
HBOT with glucose restriction, such as with the KD, elicit synergistic effects in vivo [5].  
Combining ketosis with hyperbaric oxygen may specifically target cancer metabolism while 
supporting the health of normal tissues and preventing the many negative symptoms of disease 
and standard care, like metabolic syndrome and radiation necrosis [31, 32].  We and others have 
shown that many cancers are unable to effectively metabolize ketones; however, they are an 
efficient and protective energy source for healthy tissues [6, 19, 33].  Ketone metabolism 
decreases ROS production and increases the endogenous antioxidant profile of cells which 
consume them [19, 34].  Since many therapies, including chemotherapy, radiation, and HBOT, 
work in part by increasing ROS production in the tumor, simultaneous ketone metabolism by 
surrounding healthy tissue may work to prevent toxic side effects in these tissues.  Both ketosis 
and HBOT have been shown to sensitize tumors to radiation and chemotherapy [35-38].  
Concurrent administration of these therapies may allow for the delivery of standard care at 
reduced doses, lessening toxic side effects and supporting the health of the individual.  
Importantly, βHB did not decrease ROS production in the VM-M3 cells (Figure 5.3), further 
supporting the notion that these cancer cells are not able to metabolize ketones as healthy cells 
do.   
Both βHB and HBOT significantly decreased HIF-1α expression in VM-M3 cells (Figure 
5.3), suggesting one possible mechanism by which these therapies exert their anti-cancer effects.  
The HIF-1 transcription factor is overly activated in most cancers, and HIF-1α expression 
correlates strongly with cancer progression and poor prognosis in humans [39-41].  HIF-1 
signaling increases the expression of numerous genes which promote survival, proliferation, 
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angiogenesis, and mediate the Warburg effect in tumors [41, 42].  Many chemotherapeutic 
agents work in part by inhibiting HIF-1α expression, including the BCR-ABL inhibitor imatinib 
(Gleevac), the EGF receptor inhibitor gefitinib (Iressa), and the HER2neu inhibitor trastuzumab 
(Herceptin), among others [43].  Ketosis and HBOT will likely elicit similar effects on HIF-1 
signaling to these conventional therapeutics, but with significantly less adverse side effects, and 
may provide potent synergistic effects when used in conjunction with standard care.   
There is understandable concern regarding the manipulation of diet in vulnerable cancer 
patients who may find it difficult to consume adequate calories [44].  If these adjuvant therapies 
allow for decreased yet effective doses of chemotherapy and radiation, patients will likely have 
an easier time consuming enough calories to support their metabolic needs.  Indeed, late-stage 
patients given the KD report improved quality of life, and small clinical studies suggest that 
many patients are willing and able to implement the dietary restrictions of the ketogenic diet [37, 
45-47].  Simultaneous administration of a ketone supplement such as the ketone ester could 
potentially provide the same benefit of a KD without the need for such restrictive food intake [6].  
Furthermore, ketone metabolism is a protein sparing process [48].   The human brain evolved to 
metabolize ketones as a way to spare muscle protein during prolonged periods of food 
deprivation [18].  Ketogenic diets promote weight loss in overweight patients, but they are also 
known to prevent muscle wasting during physical stress, energy restriction, or starvation [49-52].  
In a small study on humans with advanced cancer and cachexia, patients maintained a positive 
nitrogen balance and gained weight when given a ketone-supplemented ketogenic diet [53].  
Indeed, an elevation in blood ketones decreases amino acid release from muscle and decreases 
hepatic gluconeogenesis of amino acids [19].  In a mouse model of cancer cachexia, mice given a 
KD had significantly smaller tumors but did not lose as much body weight as control animals 
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[54].  Furthermore, control animals had high levels of circulating catabolic factors which elicit 
triglyceride and amino acid release, but this was inhibited by βHB [53, 54].  Similar studies 
showed that in mice with a colon cancer that elicits a severe cachexic phenotype, the brain 
greatly increased expression of 3-oxoacid CoA-transferase, a ketone utilizing enzyme,  and relied 
more heavily on βHB for energy [55].  Enhancing ketone availability as an alternative fuel to the 
brain and other healthy tissues with the ketogenic diet and/or ketone supplementation will likely 
support their function during the cachexic condition.     
There is potential for synergy between these adjuvant metabolic therapies and standard 
care [47, 56-58].  Scheck and colleagues reported a significant synergistic effect of combining 
the KD with radiation therapy in a mouse model of brain cancer [35].  Other studies have 
demonstrated increased efficacy by pairing the KD with chemotherapy or pharmacological 
agents which target metabolism [37, 38].  HBOT has been investigated as a radiosensitizer in a 
number of clinical studies [57, 59].  Meta-analyses conclude that HBOT appears to have a 
neutral or inhibiting effect on cancer progression, depending on cancer type [36, 57, 60].  When 
administered concurrently with radiation, HBOT potentiates efficacy, but may also increase soft 
tissue necrosis in nearby healthy tissue [36].  Studies indicate that this adverse effect can be 
mitigated by delivering HBOT immediately prior to, rather than concurrent with, radiation 
therapy [61].  Indeed, in this study, human glioma patients receiving HBOT immediately prior to 
radiation therapy had a median survival time of 24 months, compared to 12 months in patients 
receiving radiation alone, and did not experience significant side effects [61].  As previously 
discussed, we hypothesize that ketone metabolism by the healthy tissue may also mitigate 
adverse effects and perhaps potentiate the efficacy of HBOT and/or standard care.  We 
previously showed that HBOT alone did not affect survival in the VM-M3 model, but 
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dramatically slowed progression when administered with a KD [5].  Perhaps other studies that 
found no effect of HBOT could have revealed therapeutic potential by coupling this therapy with 
ketosis, either by the KD or ketone supplementation.     
Despite 50 years of intensive research, cancer remains the second leading cause of death 
in the United States.  This is largely due to a lack of therapies effective for long-term 
management of metastatic disease, a dilemma underlined by inadequate preclinical models.  In 
this study, we evaluated the efficacy of a novel, non-toxic combination metabolic therapy – the 
ketogenic diet, ketone supplementation, and hyperbaric oxygen – in a mouse model of metastatic 
disease which we believe reliably reflects the human metastatic phenotype [1-4].  Our study 
suggests that this combination therapy presents a safe, cost-effective, adjuvant to standard care 
which could provide novel therapeutic options for patients with late-stage cancer.  We believe 
that it is critically important to evaluate non-toxic adjuvant therapies like these, and to look for 
synergistic potential with other metabolic therapies and standard care.  It is possible that we 
already possess therapeutic options which could significantly improve patient prognosis or 
outcome when delivered in the appropriate combinations. 
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CHAPTER 6: DISCUSSION – IMPLICATIONS FOR CANCER THERAPY 
 
6.1 Chapter Synopsis 
Here we describe the major findings of this work and discuss its overarching implications 
for cancer therapy.  A detailed discussion of the data has been provided in the previous chapters.   
 
6.2 Implications for Cancer Therapy 
The major goal of this dissertation work was to determine the anti-cancer efficacy of 
ketosis and HBO therapies in the VM-M3 model of metastatic cancer in vivo and in vitro, and to 
gather preliminary information on potential mechanisms of action for future studies.  These 
therapies were effective individually to varying extents, but combining a ketone-supplemented 
ketogenic diet with concurrent HBOT elicited the most significant response in this model.  Our 
work strongly suggests that inducing ketosis in conjunction with HBOT creates a physiological 
environment that is unfavorable to the progression and survival of even a highly aggressive and 
malignant cancer like VM-M3.  Importantly, this therapy targets aspects of cancer metabolism 
which are nearly universal in human cancers.  Hypoxia is a consistent feature of solid tumors; it 
is present even in relatively small tumors, and its prevalence only increases with tumor growth 
[1].  The Warburg effect is also observed in most, if not all, cancers, and its expression also 
enhances with tumor progression and invasive potential [2].  Therefore, we expect that this 
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metabolic therapy would be effective to varying degrees against most cancer types, especially 
those that form solid tumors and/or are FDG-PET positive.   
As described in chapter 2, this specific combination of therapies has the potential to 
target several malignant processes simultaneously, including inhibiting HIF-1 and insulin 
signaling as well as inhibiting inflammation, angiogenesis, lactate export, and histone 
deacetylase activity, altering ROS production and redox status, and modulating markers of EMT 
and the metastatic process.  This is very different from the use of targeted drug therapies which 
act specifically on a single genetic mutation or oncogene pathway.  Because of the variability of 
gene mutations even within a single tumor, and the remarkable mutability of the cancer genome, 
it is unlikely that even a cocktail of targeted therapies alone would successfully eliminate all 
cells of an aggressive or metastatic tumor [3].  This appears to be true, as clinical resistance 
develops against most chemotherapies, and metastatic tumors often recur following a period of 
remission.  In contrast, dysregulated metabolism appears to be a universal feature of cancer cells 
and for this reason has been called cancer’s Achilles’ heel [4].  Perhaps most importantly, the 
Warburg effect is especially critical for the function and pluripotency of cancer stem cells, the 
specific subset of tumor cells which escape treatment from standard care and are considered 
responsible for recurrence of metastatic disease [3].   
We propose that including ketosis and HBOT as a component of the standard treatment 
regimen would target a greater proportion of cancer cells simultaneously and thus provide a more 
comprehensive therapeutic response.  A pre-operative period of metabolic therapy could shrink 
tumors and reduce infiltrative spread into nearby tissues, increasing the likelihood of successful 
and complete surgical resection of tumors.  The anti-inflammatory effects of ketosis could 
replace the need for perioperative corticosteroids, which are prescribed for some patients to 
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reduce edema caused by surgery, but will also increase blood glucose levels and likely promote 
tumor growth [5, 6].  While our proposed metabolic therapy would likely kill some fraction of a 
patient’s tumor burden on its own, it would also put significant physiological stress on any 
surviving tumor or circulating cancer cells.  This metabolic stress could potentially sensitize the 
remaining cells to the effects of standard care.  Indeed, studies have suggested a unique 
synergistic response between metabolic therapies and standard care.  Scheck and colleagues 
reported complete remission in 82% of mice with glioma by pairing the ketogenic diet with 
radiation while no occurrences of remission were observed in the mice receiving either therapy 
alone [7].  Other studies have reported similar synergy between HBOT and chemotherapy or 
radiation [8-11].  Furthermore, synergy with metabolic therapy could allow for the use of smaller 
doses of cytotoxic agents, which could greatly improve patient quality of life.  Also, inducing a 
state of ketosis during radiation, chemotherapy, or targeted drug treatment could protect healthy 
tissue from the damaging effects of these therapies [12].  Inclusion of other relatively non-toxic 
metabolic drugs that target cancer metabolism, like the glutamine-binding phenylbutyrate, the 
glucose-lowering metformin, or the fermentation-inhibiting dichloroacetate, could further 
enhance therapeutic response.  Once in clinical remission, continuation of ketone 
supplementation and/or the KD, or inducing intermittent periods of ketosis, could maintain stress 
on any residual cancer cells and extend the period of remission temporarily or permanently.    
This novel combination of ketosis and HBO targets the dysregulated metabolic pathways 
that play vital roles in every step of cancer progression.  The significant response reported here 
in the highly aggressive VM-M3 model is encouraging and strongly suggests that this therapy 
could be effective against metastatic tumors which are notoriously difficult to treat.  In order to 
maximize therapeutic response, it will be important to test the effects of ketosis and HBOT as 
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part of a well-planned and comprehensive therapeutic regimen which will likely consist of a 
variety of metabolic therapies coupled to standard care.  It is also possible that metabolic therapy 
could provide an effective, front-line treatment regimen for certain cancer types.  Thus, it is 
critical that these cost-effective, readily implementable, non-toxic therapies are tested in a variety 
of preclinical and clinical settings to determine the extent of their therapeutic potential.  We 
propose that combination ketosis and HBO metabolic therapy could offer novel therapeutic 
options for, and improve the outcome of, many patients – including those with aggressive or late-
stage cancer.   
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APPENDIX A: MATERIALS AND METHODS 
 
A.1 Ethics Statement 
 All animal studies were approved by and preformed within strict adherence to the 
University of South Florida’s Institutional Animal Care and Use Committee (IACUC) protocols 
R4137 and R00006.   
 
A.2 Materials and Methods for Included Manuscripts  
A.2.1 Materials and methods pertaining to the following experiments are described in Poff, et al, 
The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic 
Metastatic Cancer, PLOS One, 2013.  See Appendix C.    
 VM/dk mouse husbandry 
 Cell culture 
 VM-M3/Fluc inoculation for tumor implantation 
 Diet therapy  
 Hyperbaric oxygen therapy  
 Blood glucose and ketone measurements 
 Weight measurements 
 Ex Vivo bioluminescent imaging and tumor growth analysis 
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 Survival analysis 
 Statistics 
 
A.2.2 Materials and methods pertaining to the following experiments are described in Poff, et 
al, Ketone supplementation decreases tumor cell viability and prolongs survival of mice with 
metastatic cancer, Int. J. of Cancer, 2014.  See Appendix C.   
 Cell culture 
 VM-M3 proliferation 
 VM-M3 Viability 
 VM/dk mouse husbandry 
 VM-M3/Fluc inoculation for tumor implantation 
 Ketone supplementation and diet administration 
 Blood glucose and ketone measurements 
 Weight measurements 
 In Vivo bioluminescent imaging and tumor growth analysis 
 Survival analysis 
 Statistics 
 
A.2.3 Materials and methods pertaining to the following experiments are described in Poff, et 
al, Non-toxic metabolic management of metastatic cancer in VM mice: Novel combination of 
ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy, (Accepted with 
revisions, PLOS One).  See Appendix C.   
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 Cell culture 
 VM/dk mouse husbandry 
 VM-M3/Fluc inoculation for tumor implantation 
 Dietary administration 
 Hyperbaric oxygen therapy  
 Blood glucose and ketone measurements 
 Weight measurements 
 In Vivo bioluminescent imaging and tumor growth analysis 
 Survival analysis 
 VM-M3 cell proliferation 
 VM-M3 cell viability 
 VM-M3 cell ROS detection 
 Western blot analysis  
 Statistics  
 
A.3 Materials and Methods for Unpublished Supporting Data 
A.3.1 Western Blot Analysis of pAkt (Figures 3.8, 4.2) 
 VM-M3 cells were grown for 7 days in control media with or without 5mM βHB or daily 
HBOT (100% O2, 2.5 ATA, 90 min).  Media was replaced every 48 hours during the treatment 
period.  Cells were collected by scraping and protein was extracted with sonication in HEPES 
lysis buffer containing protease and phosphatase inhibitors.  Protein isolate was separated on a 4-
20% Criterion™ Gel (Bio-Rad) and electrotransferred onto a nitrocellulose membrane.  
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Membranes were blocked with 5% non-fat dry milk and immunoblotted with anti-phospho-Akt 
(Ser473) rabbit monoclonal antibody (1:1000, Cell Signaling #4060S) and HRP-conjugated goat 
anti-rabbit secondary antibody.  Membranes were also probed with anti-pan-actin rabbit 
polyclonal antibody (1:2000; Cell Signaling #4968S) as a loading control.  Bands were imaged 
on film using a standard chemiluminescent visualization protocol and band density was 
determined with Image J software (NIH).  Statistical analysis was performed using unpaired t-
tests.  Results were considered significant when p<0.05.      
 
A.3.2 Histological Analysis of Tumor Morphology and Immunohistochemical Analysis of 
Tumor Vascularization (Figures 3.7, 4.11, 5.7) 
 Approximately 106 VM-M3/Fluc cells in 300 µL sterile PBS were subcutaneously 
implanted into the abdomen of 2-4 month old male VM/dk mice.  On the day of inoculation, 
mice were randomly assigned to either control or treatment groups (N=8).  Control animals were 
fed standard rodent chow (2018 Teklad Global 18% Protein Rodent Diet, Harlan) ad libitum.  
Treated animals received KD-USF (Harlan Laboratories), a custom- designed ketogenic diet, 
with 10% KE mixed in by weight, fed ad libitum, and HBOT sessions (100% O2, 2.5 ATA, 90 
min) three times per week.  The macronutrient profile and caloric density of SD, KD-USF, and 
KE are shown in Table 2.  After 21 days, animals were humanely euthanized and livers were 
harvested and preserved in 10% neutral, phosphate buffered formalin.  The liver tissue was 
paraffin-embedded, cut into 5 micron sections, and mounted onto microscope slides at the USF 
Morsani College of Medicine Histology Core.  One set of slides was stained with hematoxylin 
and eosin and mounted with cover slips for morphological analysis.  Another set of slides was 
probed for the endothelial cell marker CD31 to visualize blood vessels.  These slides were 
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rehydrated through a series of xylene and ethanol washes, and antigen was retrieved by a 
standard heat-mediated citrate buffer method.  Slides were incubated in 0.3% H2O2 in dH2O to 
inhibit endogenous peroxide activity.   Immunohistochemical analysis of the slides was 
performed using the VECTASTAIN Elite ABC kit.  Slides were blocked for 30 minutes in 
normal blocking serum, and then incubated in anti-CD31 antibody (1:25; ab28364, Abcam) for 
one hour at room temperature.  Slides were then incubated in biotinylated anti-rabbit secondary 
antibody in normal blocking serum for 30 minutes at room temperature, followed by 
VECTASTAIN ABC reagent containing avidin and biotinylated horseradish peroxidase solution 
for 30 minutes at room temperature.  Slides were developed using the VECTOR NovaRED 
Peroxidase (HRP) Substrate Kit.  Slides were counterstained with hematoxylin, washed, mounted 
with coverslips, and visualized with light microscopy.  At least 3 frames containing tumor tissue 
per sample were analyzed.  The number of CD31+ blood vessels associated with tumors in each 
frame was counted and compared between control and treated groups as a measure of tumor 
vascularization.  Statistical analysis was performed with unpaired t-test.  Results were considered 
significant when p<0.05.      
 
Table A.1.  Macronutrient profile and caloric density of diets and ketone supplements. 
Macronutrient 
Information 
Standard 
Diet (SD) 
Ketovolve 
(KD) 
KD-USF 
(KD2) 
1,3-
Butanediol 
(BD) 
Ketone Ester 
(KE) 
% Cal from Fat 18 89.2 77.1 N/A N/A 
% Cal from 
Protein 24 8.7 22.4 N/A N/A 
% Cal from 
Carbohydrate 58 2.1 0.5 N/A N/A 
Caloric Density 3.1 Kcal/g 7.12 Kcal/g 4.7 Kcal/g 5.58 Kcal/g 6.0 Kcal/g 
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A.3.3 Chronic Oral Administration of Ketone Supplements in Rats (Fig. 4.13-4.16, Table 1) 
A.3.3.1 Intragastric Gavage to Induce Ketosis with BD and KE 
 Male Sprague-Dawley rats (275-325 g) were purchased from Harlan Laboratories and 
shipped directly to the USF Morsani College of Medicine Vivarium for this study.  Rats received 
a daily 5g/kg dose of either water (control), BD, or KE via intragastric gavage for 29 days (N=8).  
Gavage was performed at the same time daily, and rats were weighed weekly to ensure proper 
dosing.   
 
A.3.3.2 Blood Glucose, Ketone, and Lipid Measurements (Figures 4.13 – 4.16) 
 On the first day (day 0), and every 7 days for the duration of the study (days 7, 14, 21, 
28), blood glucose and βHB were measured over the 8 hours following water or ketone 
supplement administration.  Animals were fasted for 4 hours (water available) prior to 
intragastric gavage to stabilize blood metabolites.  Immediately prior to (baseline), and 0.5, 1, 4, 
and 8 hours following intragastric gavage, whole blood samples (approximately 10 µL) were 
taken from the saphenous vein to measure blood glucose and βHB with the Precision Xtra™ 
Blood Glucose & Ketone Monitoring System (Abbott Laboratories).  On day 0 and 28, baseline 
blood cholesterol, high density lipoprotein (HDL), and triglycerides were measured with the 
CardioChek™ blood lipid analyzer (Polymer Technology Systems, Inc.).  Low density 
lipoprotein (LDL) levels were derived using the Friedewald equation: LDL = Total Cholesterol – 
HDL – (Triglyceride/5) [1, 2].  Statistical analysis was performed with one-way ANOVA.  
Results were considered significant when p<0.05.       
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A.3.3.3 Metabolomics Profiling of KE Treated Rats (Table 4.1) 
On day 29, approximately 500 µL of whole blood was collected from the saphenous vein 
of control and KE-treated rats 4 hours after intragastric gavage.  Serum was separated by 
centrifugation using Microtainer® Tubes with Serum Separator (Becton Dickinson).  Serum was 
transferred to screw-top cryovials and flash frozen in liquid N2.  Frozen serum samples were 
shipped to Metabolon, Inc. for global metabolomics profiling using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS).  
The concentration of 388 named biochemical of known identity were analyzed in the serum 
samples.  Welch’s two-sample t-test was used to determine which metabolites differed 
significantly in concentration between control and KE-treated animals.  Results were considered 
significant when p<0.05.      
   
A.3.4 Ketone-Supplemented Ketogenic Diets Survival Study (Figures 4.7 – 4.12) 
 Approximately 1 million VM-M3/Fluc cells were implanted s.c. into the abdomen of 2-4 
month old male VM/dk mice.  On the day of inoculation, mice were randomly assigned to either 
control, KD+BD, or KD+KE (N≥7).  Control mice were fed standard rodent chow (2018 Teklad 
Global 18% Protein Rodent Diet, Harlan) ad libitum.  KD+BD-treated mice were fed KD-USF 
mixed with 20% BD and 1% saccharin (for palatability) by weight ad libitum.  KD+KE-treated 
animals were fed KD-USF mixed with 10% KE and 1% saccharin (for palatability) by weight ad 
libitum.  The macronutrient profile and caloric density of SD, KD-USF, BD, KE are provided in 
Table A.1.  The methods regarding blood glucose and ketones, weight, tumor growth, metastatic 
spread, and survival analysis were the same as previously described (Chapters 3, 4) [3, 4].   
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A.3.4 Metastatic Spread - Ex Vivo Organ Bioluminescence (Figures 4.10 and 5.6) 
 Approximately 1 million VM-M3/Fluc cells implanted s.c. into the abdomen of 8-16 
week old male VM/dk mice.  On the day of inoculation, mice were randomly assigned to either 
control or treatment groups (N=8).  Control mice were fed standard rodent chow (2018 Teklad 
Global 18% Protein Rodent Diet, Harlan) ad libitum.  KD+KE and KD+KE+HBOT-treated 
animals received KD-USF with 10% KE and 1% saccharin by weight ad libitum.  
KD+KE+HBOT mice also received HBOT (100% O2, 2.5 ATA, 90 min) three times weekly.  
The macronutrient profile and caloric density of SD, KD-USF, and KE are provided in Table 
A.1.  After 3 weeks, animals were humanely euthanized, and brain, lungs, liver, kidneys, spleen, 
and a sample of adipose tissue were harvested.  The organs were immediately placed in a petri 
dish containing 300 µg/mL sterile PBS for 5 min.  Ex vivo organ bioluminescence was then 
measured using the IVIS Lumina cooled CCD camera system and Living Image® software 
(Caliper LS). Bioluminescent signal (photons/sec) of each organ was used to compare extent of 
metastatic spread between control and treated animals.  Statistical analysis was performed with 
unpaired t-test.  Results were considered significant when p<0.05.   
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